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 The overall goals of this project were to develop microstructurally based constitutive 
models to characterize the mechanical behavior of arteries and to investigate the effects of HIV 
proteins and antiretroviral drugs on the microstructure and mechanical behavior. To this end we 
created several constitutive models in aim 1 using a rule of mixtures approach, investigated the 
role of viral proteins in aim 2 through the use a transgenic mouse model, and studied the effects 
of the antiretroviral drug AZT administered to mice in aim 3.   
 It is well known that the local mechanical environment which cells experience mediates 
growth and remodeling and that subsequent growth and remodeling can change that mechanical 
environment. This remodeling includes changes in the content and organization of the 
constituents of arteries (collagen, elastin, and smooth muscle cells). The first aim thus created 
models that incorporated the content and organization of these constituents using a rule-of-
mixtures approach.   The models we developed were able to capture the mechanical behavior of 
the arteries as well as previously developed phenomenological models while providing more 
physical meaning to the parameters, some which can be measured experimentally for 
incorporation into future models.   
 Aims 2 and 3 investigated the mechanical and microstructural changes to murine arteries 
in response to HIV proteins or the drug AZT.  While the development of antiretroviral therapy 
has greatly increased the life expectancy of patients with HIV, a number of other complications 
and co-morbidities including cardiovascular disease have become apparent.  While clinical data 
has implicated both the virus and the antiretroviral drugs as playing roles, this work addressed 




models and focused on the two subclinical markers of increased intima-media thickness and 
arterial stiffening.  
 Aim 2 used a transgenic mouse that expressed most of the human HIV proteins.  We 
observed both intima-media thickening and arterial stiffening in alignment with clinical data.  
Other changes that also support a proatherogenic phenotype included decreased elastin content 
and changes in cathepsin activity.  Aim 3 administered the antiretroviral drug AZT to healthy 
mice and we also observed the same subclinical markers of atherosclerosis including intima-
media thickening and arterial stiffening as well as the other proatherogenic changes of decreased 
elastin and changes in cathepsin activity.  Several other parameters including axial behavior, 
opening angles, collagen content, and collagen fiber angles were also quantified. These were 
important to fully characterize the vessel and may also be incorporated in the future into the 
constitutive models developed in aim1.   
 In conclusion, in aim 1 we developed a microstructurally based constitutive model of 
arteries that effectively captures the mechanical behavior and includes parameters that have more 
physical meaning and some of which are experimentally tractable.  Aims 2 and 3 both observed 
several subclinical markers of atherosclerosis in mice that express HIV proteins or were given 
AZT, providing a good model for future work and suggesting that both the HIV virus and 
antiretroviral drugs may play roles in the development of atherosclerosis in HIV.     









 Acquired immunodeficiency syndrome (AIDS) is considered a global epidemic 
with human immunodeficiency virus-1 (HIV-1), the causative agent of AIDS, having a 
worldwide prevalence of over 34 million people (1). Due to the success of highly active 
antiretroviral therapy (HAART), HIV-1-infection has been transformed from a terminal 
diagnosis to a manageable chronic disease. HIV patients, however, have an elevated 
incidence of dyslipidemia, lipodystrophy, insulin resistance, diabetes mellitus, and 
cardiovascular disease (CVD); the latter includes an elevated risk of myocardial 
infarction (2-4) and higher prevalence of atherosclerotic lesions (5-7), as well as 
increases in markers of subclinical atherosclerosis including increased carotid artery 
intima-media thickness (8-13), increased arterial stiffness (8, 14, 15) and impaired flow-
mediated brachial artery dilation, an indicator of endothelial dysfunction (8, 9, 14, 16-
20).  
 Despite the numerous clinical studies, the roles and importance of the HIV-1 virus 
and the HAART drugs in causing these changes still remains unclear. Discrepancies exist 
between various studies due to the inability to control other cardiovascular risk factors 
such as age, gender, weight, cholesterol levels, smoking, and hypertension in all patients 
as well any confounding effects from different stages of HAART therapy. This study 
seeks to further investigate the independent roles of the HIV-1 virus and the HAART 
drug AZT in the development of cardiovascular disease, with emphasis on the 




  Towards this end, in Aim 1 we developed and tested a novel microstructurally-
based constitutive model, capable of integrating tissue-level and microstructure 
biomechanical measurements. Specifically, this model can incorporate the relative 
content and organization of elastin, collagen, and smooth muscle cells comprising the 
vessel wall and provides a framework to integrate tissue level mechanical changes (e.g., 
arterial stiffening) with microstructural level changes (e.g., elastin fragmentation) (21-
23). In aims 2 and 3 we quantified these biomechanical and microstructure 
measurements, in parallel with molecular markers of vascular remodeling, in common 
carotid arteries and aortas in an HIV-1 transgenic mouse model and mice administered 
the HAART drug AZT. 
1.2 Specific Aim 1 
Develop a microstructurally based constitutive model of arteries.  
 Mechanically mediated vascular remodeling occurs as vascular cells sense and 
respond to their local mechanical environment. Thus, fundamental to many studies of 
vascular remodeling is the quantification of the local mechanical environment under 
specific loading conditions; i.e., determining the distribution of stresses and strains of a 
vessel under applied loads (e.g., pressure, axial extension, luminal flow, etc.) Knowledge 
of the constitutive behavior of the vessel wall allows one to predict the local stresses and 
strains throughout the wall for a vessel of known geometry and applied loads. Given that 
the material response of biological tissues is governed by their internal structure (i.e., cell 
and extracellular matrix content and organization), the goal of this aim is to create a 




in various components determined experimentally as in the previous two aims can be 
incorporated into the model in the future.    
1.3 Specific Aim 2 
Characterize the mechanical behavior, microstructure, and protease activity of 
arteries from a HIV-1 transgenic mouse model. 
 Clinical studies have shown that HIV-1 patients show early signs of 
atherosclerosis such as arterial stiffening and carotid intima-media thickening.  However, 
the role of viral proteins and HAART drugs in these symptoms remains unclear.  
Therefore, the goal of this aim was to isolate the effects of the viral proteins on the 
arterial behavior through the use of a HIV-1 transgenic mouse model (HIV-1 Tg).  These 
mice express all of the HIV-1 genes except for gag and pol and therefore the blood has 
circulating proteins that can interact and affect the arteries as in HIV patients. We 
hypothesized that common carotid arteries and aortas from HIV-1 Tg mice would exhibit 
increased arterial stiffness and intima-media thickness compared to their littermate 
controls and that these differences would correlate with differences in collagen and 
elastin content and organization, and cathepsin L, S, and V activity. 
1.4 Specific Aim 3 
Characterize the mechanical behavior, microstructure, and protease activity of 
arteries from wild type mice given the antiretroviral medication AZT. 
 The various HAART drugs are also known to have negative effects on endothelial 
and vascular cells that could contribute to the increased cardiovascular disease in HIV 
patients.  However, more in vivo data related to HAART’s effects on the arterial wall is 




arterial behavior through the administration of the nucleoside reverse transcriptase 
inhibitor (NRTI) drug azidothymidine (AZT) via oral gavage to otherwise healthy 
FVB/N mice. We hypothesized that the common carotid arteries and aortas from AZT 
treated mice would exhibit increased arterial stiffness and intima-media thickness 
compared to sham-fed controls and that these differences would correlate with 







Background and Literature Review 
2.1 Arteries 
 Arteries and veins are the two major types of blood vessels within the 
cardiovascular system.  Veins serve to return circulating blood to the heart while arteries 
are the conduits that carry blood away from the heart to the rest of the body to 
deliversoxygen and nutrients to the tissues.  The arterial wall is a multilayered structure 
with the ability to sense and respond to changes in both blood pressure and flow in short 
time frames (dilation or constriction) or long term (growth and remodeling).  The three 
layers that comprise the blood vessels are the intima, media, and adventia. (24, 25)  The 
intima is the inmost layer and is primarily a single layer of endothelial cells on a 
basement membrane that line the lumen.  The health and integrity of the cell layer is 
important as they provide a non-thrombogenic surface for blood flow as well as sense 
changes in flow or pressure and release signaling molecules such as nitric oxide (NO) and 
endothelin-1 (ET-1) to the outer layers of the vessel. The middle layer is the media, 
which is comprised of concentric layers of smooth muscle cells (SMCs) and elastin, 
which form elastic lamellae. These smooth muscle cells provide the ability of the artery 
to contract and dilate. The outermost later of arteries is the adventia, which is comprised 
primarily of collagen and fibroblasts and some larger vessels (aorta) also has a vasa 
vasorum, which are a small blood vessel network to nourish the vessel wall itself.  When 
healthy, arteries are able to supply proper blood flow to all the body’s tissue, but various 
perturbations in the healthy homeostatic state can lead to damage or disease that impair 




2.2 Cardiovascular Disease and Atherosclerosis 
 Cardiovascular disease (CVD) is widespread in the United States with one in every 
three deaths in 2008 attributed to some form of CVD (26).  Many of these cardiovascular 
events occur as a consequence of atherosclerosis in the arteries.  Atherosclerosis is a 
condition in which fat, inflammatory cells, and scar tissue accumulate in the arterial wall 
(26).  Atherosclerosis is considered an inflammatory disease since immune cells play a 
large role in its development (27).  The initiation of the disease is unclear but has been 
linked to hemodynamics, specifically regions of oscillatory flow or low shear stress, 
damage and dysfunction to the endothelial layer of the arterial wall, increased cholesterol 
or cytokine levels in the blood, amongst other factors (27-30).  Once activated by any one 
of these mechanisms, the endothelial cells begin to express factors such as vascular cell 
adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), that 
promote the binding of monocytes and T lymphocytes circulating in the blood.  The 
adhered monocytes then migrate through the endothelial layer into the arterial wall in a 
process thought to be promoted the expression of factors such as monocyte 
chemoattractant protein 1 (MCP-1). (27, 29, 31, 32)  Once in the wall, the monocytes 
differentiate into macrophages that express receptors such as scavenger receptor A and 
CD36 which allow them to internalize and accumulate lipoproteins.  Macrophage 
colony–stimulating factor (M-CSF) and a number of signaling molecules produced by 
endothelial and smooth muscle cells promote this transition. (27, 32)  Within the wall, the 
macrophages continue to internalize lipids until they become lipid laden foam cells.  
They also replicate as well as release cytokines including iterleukin-1 (IL-1) and tumor 




33) Smooth muscle cells also release a number cytokines including platelet derived 
growth factor (PDGF), transforming growth factor-beta (TGF-β), and interferon gamma 
(IFNγ). (31)  The accumulation of these fat laden macrophages characterizes the early 
stage of atherosclerotic lesions known as fatty streaks. (34)  The lesions continue to grow 
and narrow the lumen as smooth muscle cells take on a more “synthetic” phenotype in 
which they have increased proliferation and producuction of extracellular matrix (ECM) 
specifically collagen.  Also, in lipid rich lesions it has been shown the smooth muscle cell 
have increased proteoglycan production which can more easily entrap LDL (low-density 
lipoprotein). Smooth muscles may contribute to the formation of a lipid laden core of the 
lesions themselves as they have been shown to express cholesterol and LDL receptors in 
the presence of various cytokines. (31)   
 Increased levels of reactive oxygen species are also associated with 
atherosclerotic vessels.  While healthy vessels generate reactive oxygen species (ROS), 
which play roles in important signaling pathways, in atherosclerotic arteries, the levels of 
ROS are increased and can lead to negative effects on the vessels.  The endothelial 
dysfunction and impaired vasodilation associated with ROS are primarily due to a 
decrease in the availability of nitric oxide (NO). Nitric oxide production is normally 
highly regulated by the level of eNOS (endothelial nitric oxide synthase) production 
within the cells; however, the regulation pathways for eNOS are closely related to redox 
pathways and thus increased ROS can disturb eNOS synthesis leading to decreased NO 
and endothelial dysfunction. (35)  Other deleterious effects of disturbances in ROS, 
eNOS, and NO regulation include increasing leukocyte adhesion molecules like VCAM-




macrophages uptake as they transition to foam cells.  The ox-LDL can also further 
exacerbate the decreased NO and endothelial cell inflammatory responses. Furthermore, 
increased ROS and decreased NO are thought to cause increased SMC proliferation, 
migration, and transition to a “synthetic” phenotype. (33, 35, 36)    
 While extracellular proteases play many important roles in healthy vessels 
including remodeling and healing, deregulation of the enzymes is also associated with 
various vessel pathologies. Proteases are a family of enzymes that irreversibly hydrolyze 
peptide bonds and are most commonly known for their ability to degrade ECM.  The best 
know group of proteases are metalloproteinases, which have an active site that contains a 
metal atom (usually zinc). (37) Two other groups are serine proteases and cysteine 
proteases which include cathepsins. Originally cathepsins were thought to act primarily 
intracellularly to degrade proteins in the lysosomes, but a number of cells including 
macrophages, smooth muscle cells, and endothelial cells can transport cathepsins out of 
the cells for degradation of proteins extracellularly. (37)  Studies have shown that 
protease activity (including cathepsin activity) is increased in atherosclerotic vessels. 
Macrophages that have migrated into the walls are thought to be a primary source of the 
increased levels of protease expression, though endothelial and smooth muscle cells also 
contribute. Histology of plaques has shown enlarged lysosomes in both macrophages and 
smooth muscle cells. (37, 38)   Specifically, cathepsins S and K were found in the fibrous 
cap, foam cells, and adjacent to SMCs in atherosclerotic vessels, while healthy vessels 
had negligible cathepsins as detected by immunohistochemistry and Western and 
Northern blots.  Extracts from the atherosclerotic tissue have shown that the cathepsins 




with interferon gamma (IFNγ), interleukin-1 beta (IL-1β), or tumor necrosis factor-α 
(TNF-α),  cytokines released by cells during plaque formation, induced cathepsin S 
production and degradation of elastin. (38, 39)  Increased proteolysis by the cathepsins 
(and other proteases) is thought to contribute progression of the disease by weakening the 
arterial wall and allowing infiltration and migration on monocytes into the wall and 
SMCs from the media to intima.  Specifically, cathepsin S-deficient monocytes are not 
able to migrate through membranes containing an endothelial monolayer, collagen, and 
SMCs. (39)  Additionally, increases in protease activity are thought to degrade the ECM 
of the fibrous cap over the plaque helping to lead to either erosion or rupture. (37, 38)    
 Atherosclerotic lesions are dangerous because they can lead to thrombosis and 
occlusion of the blood vessel.  Thrombosis typically occurs as a result of either erosion or 
rupture of the plaque.  Erosion damage occurs when the endothelial cells lining the vessel 
lumen become disrupted; this desquamation of the lumen exposes the underlying 
collagen to the blood which can activate platelets and trigger thrombosis. (27)  The other 
and most common form of plaque disruption leading to thrombosis is plaque rupture.  
This typically occurs in plaques that have developed a very thin fibrous cap over a large 
lipid laden region.  When the plaque ruptures, its contents come in contact with the 
bloodstream leading to thrombus formation. In some cases the thrombosis may not 
completely occlude the vessels, but instead it will heal itself creating with thick fibrous 
lesion that even more significantly narrows the lumen.  (27) 
 While plaque erosion or rupture can be catastrophic to the patient, many people 
present few symptoms until thrombosis occurs.  However, the American Heart 




can assess people’s risk factors for the disease.  These subclinical markers include 
coronary artery calcification (CAC), increased carotid intima-media thickness (cIMT), 
increased arterial stiffness (or vascular compliance), and impaired brachial artery flow-
mediated dilation (FMD). (26) Coronary artery calcification, which is measured using 
computed tomography (CT) of chest, detects calcium deposits in the arteries which 
indicate some degree of atherosclerosis including levels below clinically significant 
lesions.  Carotid intima-media thickness (cIMT) which is assessed via ultrasound is 
considered to be an even earlier marker of atherosclerosis since thickening is thought to 
occur prior to early lesion formation including calcification. Arterial stiffness can be 
measured directly in arteries that may be accessed via ultrasound (e.g., common carotid, 
brachial, femoral arteries). Pulse wave velocity, measured by applanation tonometry is 
another measure used to assess arterial stiffness of the aorta. Flow mediated dilation is 
measured by ultrasound; the brachial arterial diameter is measured before and after 5-
minutes of occlusion with a blood pressure cuff, which induced reactive hyperemia. 
Reactive hyperemia and high post-occlusion flow stimulates nitric oxide release, 
resulting in vasodilation; impaired FMD indicates endothelial function.  The last three of 
these techniques allow noninvasive early detection of atherosclerosis risk factors before 
any detectable plaques are formed and may provide a way for doctors to monitor patient’s 
risk factors and health.   
2.3 Pathology of HIV-1 
 The Acquired Immune Deficiency Syndrome (AIDS) is a global epidemic with 
over 34 million people worldwide living with infection with the human 




lentivirus family of retroviruses, which contain RNA that is converted to DNA in the cell 
with a reverse transcriptase enzyme.    HIV-1 can infect a variety of cells in the body; 
however, it primarily infects CD4 positive lymphocytes. The virus binds to the CD4 
surface protein before entering the cell, which causes a conformation change that enables 
fusion and entry into the cell (41).  HIV is replicated mostly in helper T cells (CD4+) but 
is also found in macrophages, monocytes, B lymphocytes, natural killer cells, 
eosinophils, and dendritic cells.(41)  The progression from initial infection to the 
development of AIDS is marked by an increased viral count and a decrease in the 
quantity of T cells.  Cell death is thought to be primarily caused by accumulation of viral 
DNA in the cytoplasm or induced apoptosis.  This decrease in helper T cells prevents the 
activation of other immune cells in response to future infections making the person more 
susceptible to opportunistic infections.  These secondary opportunistic infections are 
often the cause of death in patients with advanced AIDS.   
 The virus contains nine genes; the gag and env encode the structural proteins, the 
pol gene encodes the reverse transcriptase, and the other 6 genes, tat, nef, rev, vif,  fpr, 
and vpu encode for regulatory proteins.  The viral replication process consists of several 
steps.  First, the viral envelope must bind to the specific cell surface receptor on the host 
cell; specifically, the gp120 protein of the env gene binds to CD4 receptor as well as to 
CC and CXC chemokine receptors.  Next, the gp41 tail on the envelope undergoes a 
conformation change that pulls the cell membrane and viral envelope together to promote 
fusion and thus entry of the virus into the cell.  The viral RNA is transported into the host 
cell’s nucleus where the reverse transcriptase in the pol gene helps transcribe the RNA 




help of the integrase protein in pol. The newly inserted viral genes are then transcribed 
more quickly with the aid of the tat protein.  These new transcripts are transported to the 
cytoplasm in a process regulated by rev. Once in the cytoplasm the RNA is either 
packaged or translated in proteins.  The structural proteins from gag and env move 
towards the cell surface, and the virus begins the budding process eventually separating 
from the host cell as a newly formed viral particle containing proteins and RNA 
transcripts.  During the budding processes the protease (pol gene) must cleave several 
precursor proteins into their mature form in order for the virus to mature and have ability 
to infect new cells (42).  
2.4 Antiretroviral Therapy 
 Since it was recognized that AIDS is caused by a virus, a number of drugs that 
attempt to prevent viral replication by inhibiting the virus at various stages within its 
replication cycle have been developed.   There are six types of drugs: nucleoside reverse 
transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs), integrase inhibitors, entry inhibitors (EIs), and CCR5 
co-receptor antagonists (43, 44).  Specifically, for highly active retroviral therapy 
(HAART) patients are given a combination of three drugs with typically at least one 
NRTI and a PI or NNRTI (45).   
 The first antiretroviral drug developed was azidothymidine, AZT, which is a 
nucleoside reverse transcriptase inhibitor (NRTI).  NRTI’s name is due to its similarity to 
the nucleosides that are the building blocks of RNA and DNA.  However, these drugs 
differ from natural nucleosides in that their hydroxyl group (-OH) is replaced with 
another group that makes them incompatible with DNA elongation.  Therefore, the drugs 




transcription of the viral RNA into DNA. (46)  Nonnucleoside reverse transcriptase 
inhibitors (NNRTIs) are a class of drugs that also interfere with reverse transcription 
stage of the viral cycle; however, NNRTIs bind to the viral reverse transcriptase enzyme 
preventing it from functioning. (46) 
 The HIV-1 protease enzyme is important in producing functional and infectious 
viral particles by cleaving the polypeptide chains to allow the proper proteins to fold and 
form.  Protease inhibitors (PI) are a class of ARV’s that interfere with the function of the 
protease’s enzymatic actions prevent the viral particles that are produced from becoming 
mature infectious viruses capable of further replication. (46) Integrase inhibitors similarly 
bind to the viral integrase enzyme inhibiting the virus’s ability to incorporate the viral 
DNA into the host cell DNA which is necessary for replication as RNA transcripts for 
new particles are made from the viral DNA once incorporated in the host cell DNA. (44)  
Entry inhibitors (EIs) or fusion inhibitors bind to the gp41 protein on the viral membrane. 
This prevents the protein from undergoing the necessary conformational changes to pull 
the virus closer to the cell membrane and eventually facilitate fusion of the virus to the 
cell and entry of its contents. (46)  The newest class of antiretroviral medications is 
CCR5 co-receptor antagonists, which differ from the others in that they bind to the host 
cell rather than the viral components.  Specifically, they bind the CCR5 co-receptor on 
the cell surface preventing the virus from binding and thus inhibiting viral infection of the 
cells. (44)  Currently, many studies are trying to optimize the treatment of patients with 
resistance or poor response to previous drug regimes by incorporating the newer drugs in 





2.5 Non-AIDS Related Complications 
 The development and implementation of HAART has been effective at delaying 
the progression to the development of AIDS and increasing the life expectancy of HIV 
positive patients to begin to approach normal life expectancy. (47)  However, the longer 
lifespan has led to the emergence of a number of other complications and conditions that 
were not observed prior to widespread use of HAART. (48)  Several different serious 
(potentially fatal) infections are still prevalent in HIV patients, despite the immune 
recovery on HAART. (49)  In particular, tuberculosis (TB) rates among HIV patients are 
still significantly higher than the general population.  This could be partially due to the 
difficulty in diagnosing latent TB before starting HAART; the decision of when to start 
HAART in known TB positive patients is also difficult due the potential toxicity of 
taking both antituberculosis and antiretroviral drugs at the same time. (49-51) Hepatitis B 
is also a common co-infection with HIV partially because HIV infection modifies the 
behavior of hepatitis B affecting treatment strategy. (52)  Similarly, hepatitis C is another 
common co-infection due the limited effectiveness of traditional treatments in HIV 
patients.  End-stage liver disease related to hepatitis C is one of the leading causes of 
non-AIDS related death in HIV patients.  (49, 53)   
 Cancers and malignancies are a common cause of death in HIV patients at 
incidence rates above that of the general population. However, the relationships between 
the virus, immunodeficiency, HAART, and cancer and malignancies still remain unclear.  
AIDS-defining malignancies include Kaposi sarcoma, non-Hodgkin lymphoma and 




gastrointestinal tract, liver, urogenital tract, upper airway, or other haematological 
cancers. (49, 54) 
 Many HIV patients who begin HAART treatment with late stage disease often 
have a counterintuitive decline in their health and increase in complications despite the 
recovery of their CD4+ counts.  This response known as either immune restoration 
disease (IRD) or immune reconstitution inflammatory syndrome (IRIS) is thought to be 
the result of the restored immune system’s hyperinflammatory response to any otherwise 
subclinical or quiescent pathogen. However, currently there is no standard to either avoid 
or manage the syndromes. (49, 55, 56)  
 Other complications common in HIV patients include progressive multifocal 
leukoencephalopathy, cognitive disorders, liver disease, bone and kidney disorders, and 
cardiovascular disease.  Progressive multifocal leukoencephalopathy, a fatal disease 
where the myelin sheathes of nerves become damaged, is considered an AIDS-defining 
disease due to its prevalence in HIV patients.  Interestingly, while HAART treatment 
generally leads to lower JCV (John Cunningham virus) levels (the causative agent of 
multifocal leukoencephalopathy), some patients see new onset or worsening of the 
disease following initiation of HAART, which is thought to possibly be due to increased 
inflammatory reactions with increased immune counts while on HAART. (49, 57)  
Cognitive disorders specifically dementia are also prevalent in the HIV patients, and 
while its pathogenesis is thought to be related to HIV proteins or systemic immunological 
effects, the pathways and early markers are unclear as well as the impact of HAART 
therapy. (49, 58) Non-alcoholic fatty liver disease is also common in HIV patients likely 




non-alcoholic steatohepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma. (49, 
59) Bone disorders in HIV patients include osteopenia and osteoporosis, these conditions 
occur even in HAART naïve patient indicating that the virus itself plays a significant role 
in development while the role of HAART drugs remains unknown.  (60)  Before the 
implementation of HAART, glomerular conditions were the primary observed renal 
disorder; however, since HAART, tubular disorders including Faconi’s syndrome have 
increased.  In general, renal function is closely monitored in HIV patients as diagnosed 
conditions often have a poor prognosis. (49, 61)    Finally, the incidence of cardiovascular 
disease is higher in the HIV population than the general population with studies 
suggesting that both HIV infection and HAART therapy play roles in its development. 
(49, 62-69)  
2.6 HIV and Cardiovascular Disease 
 HIV-1 patients have accelerated development of cardiovascular disease (49, 62-
71)  Due to the difficulty in conducting well controlled clinical studies, it is difficult to 
distinguish if the virus or the therapy is the major cause of the cardiovascular 
complications; however, a number of studies with varying degrees and stages of HAART 
therapy indicate that carotid intima-media thickening (cIMT) (8, 72-77), arterial 
stiffening (8, 78, 79), and endothelial dysfunction (8, 73, 78, 80, 81), early indicators in 
the development of atherosclerosis, are associated with HIV-1 in patients.  Specifically, a 
study by van Vonderen et al. found that patients with HIV infection had significant 
differences in cIMT and stiffness of the carotid and femoral arteries from healthy control 
subjects with HIV patients having both thicker and stiffer arteries.  Additionally no 




study. (77)   Another study by the same group found that while cIMT did increase for 
patients on two different HAART regimens over the course of the 24 month study, the 
carotid and brachial artery stiffness did not change though femoral artery stiffness did 
increase. (8) However interestingly, plasma indicators of endothelial function and 
inflammation including von Willebrand factor (vWF), soluble vascular cell adhesion 
molecule (VCAM-1), and soluble intercellular adhesion molecule (ICAM-1) improved 
over 24 months from the baseline values in the HAART naïve patients. This 
improvement in endothelial function markers seems to indicate that endothelial 
dysfunction may be caused by the HIV-1 virus and thus drugs to lower viral loads 
improved endothelial function.  A study by Blum et al. also seems to confirm this 
hypothesis that endothelial function is dependent on viral load. (82)  Ultrasound 
measurements of brachial artery dilation using methods for both endothelium dependent 
and independent dilation were taken in 24 HAART naïve patients with various levels of 
viral load.  Endothelium-independent vasodilation was the same between groups, but the 
group with high viral loads had significantly less endothelium-dependent vasodilation 
than the low viral load group. Even after 3 months of antiretroviral treatment, the same 
inverse correlation between viral load and endothelial function was observed.  Similarly, 
Oliviero et al. also observed both increased cIMT and impaired FMD of brachial artery in 
a cohort of HIV patients when compared to controls matched for metabolic risk factors 
(73), endothelial function was also impaired in a study in a study of low cardiovascular 
risk HIV patients (83), Hsue et al. showed that HIV patients have a larger cIMT that 




children without other cardiovascular risk factors were also found to have both arterial 
stiffening and endothelial dysfunction (78). 
 While HIV-1 is not believed to infect vascular endothelial cells in vivo, the 
dysfunction is thought to be caused by exposure of the cells to circulating infected CD4+ 
T cells, macrophages, and monocytes and HIV-1 viruses and proteins in the blood.  HIV 
infected individuals have also been shown to have higher levels of reactive oxygen 
species (ROS), which can also cause endothelial dysfunction. (81)  In particular the Tat 
protein, which is actively secreted by infected cells, has been found to have a variety of 
negative effects.  Tat has been shown to decrease the ability of pig coronary arteries to 
dilate by the inhibiting the expression of nitric oxide synthase (NOS) and thus nitric 
oxide availability. (84) A study by Park et al. exposes cultured human lung microvascular 
endothelial cells to Tat and observed another of effects the protein had on the cell 
response. They found that treatment increased the secretion of monocyte chemoattractant 
protein-1 (MCP-1); migration of CD14+ monocytes and THP-1 monocytic cells in 
transwell inserts showed that the MCP-1 from the endothelial cell supernatants was 
indeed chemoattractant and increased migration.  The study also investigated the 
signaling pathways activated by Tat that lead to the MCP-1 migration and found that 
MCP-1 was regulated by surface molecules Flk-1 and Flt-1 and PKC intracellularly. (85)  
Matzen et al. also investigated the effects of Tat on adhesion of monocytes and T-cells to 
endothelial cells.  In vitro adhesion assays showed that HIV-1 (sometimes in synergy 
with TNF-α) increased adhesion of both primary monocytes and T-lymphocytes to 
human microvascular endothelial cells. Similar results were seen using in ear venules of 




various other effects of Tat, gp120, Vpu, and Nef proteins on endothelial cells including 
expression of several cell adhesion molecules, increasing endothelial permeability, cell 
proliferation, increased cytokine signals, induced apoptosis, and increased oxidative 
stress. (81)  
2.7 HAART and Cardiovascular Disease 
 While the HIV virus itself has been implicated in the development of 
cardiovascular disease, several studies have implicated HAART in the disease 
progression. (70, 87, 88)  The various HAART drugs are also known to have negative 
effects on endothelial and vascular cells that could contribute to the increased 
cardiovascular disease in HIV patients as evidenced by increased carotid intima-media 
thickness (8, 72), arterial stiffening (8, 78, 79), and endothelial dysfunction (89-93).  In 
one clinical study by van Vonderen et al., two of the measured clinical markers of 
atherosclerosis, increased IMT in the carotid and stiffness in the femoral artery, both 
further increased even with the initiation of HAART in previous therapy naïve patients. 
(8) Increased arterial stiffness is also confirmed by another study which found exposure 
to NRTIs or PIs independent factors associated with increased stiffness as measured by 
heart rate corrected augmentation index. (79)   Blanco et al. also investigated endothelial 
function in HIV-infected patients with low coronary risk factors. (83)  The study found 
the FMD of the brachial artery was significantly reduced between the HIV patients on 
HAART and control subjects.  The HAART naïve patients showed an intermediate 
impairment of FMD but it was not significantly different from either group.    Other 
studies had similar results with HIV patients receiving PIs in their HAART regimen 




patients not receiving PIs.(89)  A study by Shanker et al. found that endothelium-
dependent dilation in arteries in the leg was impaired after healthy HIV negative patients 
were given the PI indinavir for 4 weeks. (91)  
 On an in vitro scale, NRTIs, (which includes AZT), are the class of HAART 
drugs that have been most extensively studied with respect their effect on endothelial 
cells. In particular NRTIs are thought to interfere with mitochondrial DNA replication 
and repair resulting in damage to cells. (94)   Hebert et al. found that AZT caused 
significant decreases in cellular respiration, a marker for mitochondrial activity. In the 
study, human umbilical vein endothelial cells were cultured with media containing the 
NRTI AZT, the PI indinavir, or AZT and indinavir.  They observed increases in cell 
death in all of the treated groups as well as large (3-10 fold) decreases in oxygen 
consumption and ATP production, both markers of mitochondrial function.  The 
endothelial cells also showed increased endothelin-1 (ET-1) production.  ET-1 acts as 
both a vasoconstrictor and a mitogen, and its increased production resulted in increased 
proliferation of both endothelial cells and vascular smooth muscles cells in co-culture. 
(95)    Another study with AZT found that treatment of healthy mice with AZT for 35 
days reduced the endothelial-dependent dilation of the aorta when exposed to 
acetylcholine while the non-endothelial dependent dilation response to nitric oxide (NO) 
(administered as sodium nitroprusside, SNP ) was the same for the wildtype and treated 
mice.  Additionally, the treatment had no effect on the aortic contractility when exposed 
to either potassium chloride (KCl) or phenylephrine (PE).  Additionally, the vessels had 




 The other class of HAART drugs associated with increased cardiovascular disease 
is the protease inhibitors (PIs).  The same study by Hebert et al. also found that indinavir 
(a PI) also had a negative effect on the mitochondria as evidenced by decreased oxygen 
consumption. (95)  Endothelial cells showed an increase in oxidative stress and monocyte 
adhesion in response PIs and HAART combinations was observed in a study by Mondal 
et al. (97)  Human aortic endothelial cells in culture were exposed to indinavir (PI), 
nelfinavir (PI), zidovudine/AZT (NRTI), efavirenz (NNRTI), or two different HAART 
cocktails containing AZT, efavirenz, and one of the two PIs.  Exposure to both HAART 
cocktails stimulated ROS production 1.5-2.5 fold over control (untreated) cells.  
Monocyte adhesion assays showed that both PIs stimulated adhesion while the other two 
drugs alone had little effect.  However, the combinations of the different classes in the 
HAART cocktails increased the adhesion even more the any of the drugs alone.  Both 
ELISA and RT-PCR also showed increases in the cellular adhesion molecules, which 
play a role in monocyte adhesion. Another study with human endothelial cells in vitro 
showed that culture with the PI ritonavir increased permeability, decreased the production 
of tight junction proteins, and increased the level of superoxide production. (98) 
Additionally, the PIs amprenavir, indinavir, and ritonavir have been shown to increase 
cholesterol and cholesteryl ester uptake in macrophages independent of dyslipidemia.  
This increased uptake of cholesterol is instead thought to be regulated by CD36, as 
evidenced by upregulation of CD36 in cells treated the PIs, while treatment with C36 
inhibitors prevent the increased uptake.  Additionally, mice treated with CD36 inhibitors 
showed less signs of atherosclerotic lesion formation than the control animals. (99)  The 




cells as well. Specifically, human aortic endothelial cells exposed to efavirenz showed an 
increase in the permeability of a confluent endothelial monolayer and a corresponding 
decrease in the tight junction proteins of ZO-1, claudin-1, occluding, and JAM-1.  
Staining with dihydroethidium also indicated an increase in the levels of ROS produced 
by the cells, which could potentially be the result of the observed decreased 
mitochondrial membrane potential in the treated cells. (100) In conclusion, the primarily 
in vitro work thus far shows that antiretroviral drugs do indeed have negative effects on 
the cells, but importance of these effects leading to quantifiable changes in the 
vasculature and disease states still remains to be determined.   
2.8 Vascular Mechanics 
 In vivo, arteries are under constant multiaxial mechanical loading.  Pulsatile blood 
pressure distends the vessel and induces a cyclic circumferential stress while blood flow 
through the vessel induces a shear stress along the luminal wall.  Finally the vessels are 
under an axial load in vivo, which is demonstrated by their retraction upon excision. (24)  
The means of these three stresses are defined as follows:     
       (2.1) 
where τw is mean wall shear stress, σθ is mean circumferential stress, σz is mean axial 
stress, μ is viscosity of the blood, Q is the luminal blood flow rate, ri is the inner 
(luminal) radius, ro is the outer radius, P is the transmural pressure, h the wall thickness, 
and f is the axial force. Besides changing geometric parameters (i.e. inner diameter or 
thickness) in response to mechanical perturbations, vascular remodeling can also change 

























 Previous studies have shown that vessels respond and remodel to changes in these 
loading conditions.  A well known study by Kamiya and Togawa showed that wall shear 
stress was restored to an original value in canine carotid arteries subjected to increased 
flow. (101) Clark and Glagov found that aortic thickening during development was 
correlated to mean circumferential stress, and a study by Jackson et al. indicated that 
axial stress is regulated by remodeling as well. (102, 103) In addition to restoring mean 
stress, cells also appear to respond to restore local changes in stress as well.  For example 
Matsumoto and Hayashi showed that the different layers of blood vessels thicken to 
different degrees in response to supra-physiologic loading with the inner layers 
increasing the most due to the highest stress in that layer. (104) Thus vascular cells 
including endothelial cells, smooth muscle cells, and fibroblasts have the ability to sense 
mechanical changes and respond via a variety of mechanisms including production of 
vasoactive molecules, extracellular matrix (ECM), and ECM-degrading proteases.  
Additionally, HIV-1 and HAART drugs cause physiologic changes that can perturb 
normal cell behavior and lead to changes in the vascular wall.  
2.9 Constitutive Models of Blood Vessels 
 While we know that cells respond to stresses in their local environment, these 
forces and stresses cannot be measured directly; thus there is a need to create constitutive 
models of the material behavior of the vessels in order to calculate these stresses. In order 
to develop the proper constitutive model we must first consider the characteristics of the 
blood vessel.  Specifically, arteries have a highly nonlinear behavior with an initial 
compliant region and stiffer later response.(105)  Arteries are also considered to be 




arterial behavior since the observed hysteresis indicates that the vessels are not 
completely elastic but they do have repeatable loading and unloading curves that can be 
modeled separately.(106) Histology and mechanical tests also indicate arteries are 
anisotropic with differing material properties in the circumferential and the axial 
directions, though due to symmetry they are usually assumed to have transverse or 
orthotropic isotropy.  Due to their layered natures, arteries are heterogeneous though 
intima layer is thought to have little effect on the mechanics.  Additionally, it has been 
suggested that because the adventia is relatively thin for many of the commonly studied 
arteries it can be assumed that that vessel wall is relatively homogeneous despite the 
different compositional and mechanical behavior of each layer. (25, 106, 107)   Finally, 
while it is known that arterial wall contains both solids (ECM proteins and cells) and 
water (intra and extracellular), it is often modeled as an incompressible solid rather than a 
composite mixture of solid and fluid since the movement of water in/out of the vessels is 
minimal. (25) 
 Several different groups have previously developed models for the artery with 
differing degrees of complexity.  Chuong and Fung developed a three dimensional 
constitutive relation for arteries that is still widely used for vascular modeling. (21) The 
model represents the strain energy function, W, as an exponential equation with six 
parameters that are fit to the data.  A slight variation of this model by Holzapfel and 
Weizsacker includes one more term before the Fung-type exponential to help incorporate 
the initial stiffening then softening response observed in vessels before the non-linear 
stiffening response captured by the Fung model. (108) While these early models captured 




lacked much physical meaning in terms of the arterial structure.  Thus Holzapfel 
developed a fiber model for arterial behavior, which begins to incorporate the histological 
observed structure by modeling the vessels as an isotropic non-collagenous matrix with 
two helically wound embedded fibers (collagen). (23) There were a few groups that 
developed more structural models before the Holzapfel; however, they were not widely 
adopted (109, 110).   This model by Holzapfel has been adapted by others including 
Baek, who created four fibers (axial, circumferential, and two helical) (111).   
 Many models (even the three dimensional/thick walled models) model the artery 
as a single layer; however, several groups have attempted to model the vessel as two 
layers; a media and adventitia.  The fiber model by Holzapfel was two layers with each 
layer having its own unique material parameters, fiber angles, and geometry (radius, 
thickness, and opening angles) (23). Other two layer models include earlier ones by von 
Maltzahen, Demiray and Vito, and Rachev (112, 113).  
Another feature of arteries that is neglected by most models is the active 
properties of arteries. The smooth muscle cells within the arterial wall have the ability to 
contract and relax in response to stimuli and to control the hemodynamics in the vessels.  
Therefore, the active properties also can affect the distensibility of the arteries and thus 
including them in the mechanical analysis can provide a more accurate model.  However, 
accurately determining the active response of arteries is difficult since excision and 
external manipulation of the arteries to prepare them for testing could possibly change 
their response (i.e. damage may occur); this difficulty explains the reason the active 
response of smooth muscles is often neglected from analysis.  However, several papers 




active smooth muscle. (114, 115)  Despite the numerous different constitutive models 
available there is still room for improvement to create even more structurally based 
models and develop model which not only use algorithms to fit parameters but also 
contain some experimentally tractable parameters; aim 1 of this dissertation details the 





Specific Aim 1: Develop a microstructurally based constitutive model of arteries. 
3.1 Introduction 
 Mechanically mediated vascular remodeling occurs as vascular cells sense and 
respond to their local mechanical environment. Thus, fundamental to many studies of 
vascular remodeling is the quantification of the local mechanical environment under 
specific loading conditions; i.e., determining the distribution of stresses and strains of a 
vessel under applied loads (e.g., pressure, axial extension, luminal flow, etc.) Knowledge 
of the constitutive behavior of the vessel wall allows one to predict the local stresses and 
strains throughout the wall for a vessel of known geometry and applied loads. Given that 
the material response of biological tissues is governed by their internal constitution (i.e., 
cell and extracellular matrix content and organization), many argue that a predictive, 
widely applicable constitutive relation for arteries and other soft tissues must include 
parameters that account for the underlying microstructure (116-119). Such models will be 
particularly useful in quantifying remodeling responses associated with development, 
aging, disease progression, and clinical interventions, where the evolution of structural 
parameters may be experimentally quantified.  
 In this aim, we created newly proposed constitutive models by fitting biaxial 
mechanical data from mouse carotid arteries that incorporated four structurally significant 
constituents (collagen, elastin, smooth muscle, and water) into the formulations.  We used 
previously reported biaxial biomechanical behavior and geometry of mouse carotid 
arteries exposed to normal pressure and luminal flow but altered axial extension to 




of mixtures constitutive models (121) which we compared to both the model by Chuong 
and Fung (122) and a four fiber-family model (123). In addition to minimizing the error 
between experimental data and model predictions, we imposed penalties that required 
each constituent to be structurally significant. That is, we enforced penalties that 
encouraged parameter sets in which elastin contributes significantly to the overall 
response over low loads and collagen dominates the response over high loads. These 
constraints ascribe additional microstructural ‘meaning’ to the constitutive model. 
Whereas imposing such penalties necessarily reduces the goodness of fit of model 
predictions to experimental data, we submit that the marginal reduction in the goodness 
of fit observed in our results was off-set by the improved structural interpretation.  
3.2 Methods 
3.2.1Theoretical framework 
 Kinematics: In traditional vascular mechanics, one typically considers three 













; see Chuong and Fung (122). For 
inflation and extension of an axisymmetric tube, the deformation gradient, right Cauchy 
Green strain, and Green strain tensors have components  
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) and the 
loaded length ), the components of  F ,  C , and  E  are easily calculated. 
 Unfortunately, in Gleason et al.
 
(124), opening angle measurements were not 
performed for the freshly isolated and cultured vessels. Thus, here we approached the 
problem in an inverse fashion. Let us prescribe the state of strain in the in vivo (loaded) 
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h . Now, we may define the true stress free (or natural) configuration 
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where  R





 is the axial length of a cylindrical shell for which the 












 and length , the current 
radius may be calculated via incompressibility as 
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Given these stretches the components of  F ,  C , and  E  for extension and inflation are 
easily calculated via equations 3.1.  
 Equilibrium: For inflation and extension of a long, straight, axisymmetric tube, 


























)  0 , equilibrium requires that 
    
  
  
          
  
 
                                                     (3.7) 
where  
         and                     (3.8) 
   is the so-called ‘extra’ stress due to the deformation and  W  is the strain energy density 
function. Axial equilibrium requires that the magnitude of the axial force,  f , maintaining 
the in vivo axial extension be 
 








2P) ,                                                (3.9) 
where the first term on the right hand side is due to the traction force applied to the vessel 




cap;  = 1 or 0 for a closed or open ended tube, respectively. Equation 3.9 can be written 
as 
     
  
  
                       
          (3.10)           
see Humphrey (125). For ex vivo biomechanical testing,  = 1. Given equations 3.2 and 
3.2 or 3.6 the components of the ‘extra’ stress may be calculated as 
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where i  r,,or z .  
3.2.2 Phenomenological Models 
 We considered the model of Chuong and Fung (122) and a four fiber-family 
model in addition to several variants of a rule of mixtures model to describe the 
constitutive behavior of these vessels.  
Fung Model: Consider the strain energy function of Chuong and Fung (122) 
 W  (c / 2)[e

































,                     (3.13) 
and where  c  and  
c
16
 are material parameters. Given this strain energy function, the 
components of the extra stress due to the deformation are 
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from which  P  and  
f
m




Four Fiber-Family Model: Consider a four fiber-family proposed by Baek et al. (123), 
which is a simple extension of the model proposed by Holzapfel et al. (118) and Spencer 
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 are material parameters with  k  denoting the k
th












 is the first invariant of  C ,  
k  Mk CMk  is the stretch of the 
 k
th  fiber family,  M




 cos( k )e
z
 is the unit vector along the  k
th  fiber 
direction in the reference configuration, and  
k  is the associated angle between the axial 
and fiber directions. In general, 
 
(k )2  C

sin2( k ) 2C
z
sin( k )cos( k )C
zz




 = 0 for inflation and 
extension tests, given material symmetry. In addition, we note that under compression the 
fiber-families do not contribute to the mechanical response in an exponential fashion, as 
they do in tension. Thus, when  





 = 0; therefore, we model the vessel 
under compression as a neo-Hookean material. Here, we consider four fiber families with 
 
1  = 90° (circumferential),  
2  = 0° (axial), and  
3   4   (diagonal) which is left as 














 for the diagonal fibers to ensure material symmetry) via non-linear regression. 
Given this strain energy function, the components of the extra stress due to the 
deformation are 
       
         (3.16)
 
       
      
    
          
    
    
 
     
               
 
            
    
 







       
      
    
          
    
          
               
 
            
    
 





from which  P  and  f  can be calculated via equations 3.7 and 3.10. Note that  
(3)   (4)  
is the stretch in fiber  k =3 (and  k =4).  
3.2.3 Microstructurally-motivated models: a discrete set of fibers 
 It has long been thought that elastin contributes to the highly distensible region on 
pressure-diameter curves of arteries at low pressures and collagen contributes to the stiff 
region of these curves at high pressures; see, for example, the classic paper by Roach and 
Burton (127). Smooth muscle cells also contribute significantly to the overall mechanical 
response of blood vessels, under both passive and active (contractile) conditions. Indeed, 
other key structural constituents have also been implicated as significant contributors to 
the overall mechanical response (128). The amount, organization, and mechanical state of 
key structural constituents can vary spatially in arteries and can vary temporally as 
different constituents are produced, degraded, and remodeled.  As the tissue remodels and 
grows, constituent turnover and growth can occur at different rates and to different 
extents. Constrained mixture theory provides a convenient theoretical framework for 
quantifying the spatial and temporal variations in mechanical behavior in terms of 
microstructural metrics.  
 Constitutive Equations: Non-Uniform Constrained Mixture: We will adopt a 
simple rule of mixtures approach; that is, let the total stress be given as the sum of the 
stresses borne by key, individual structural constituents. In particular, we will follow 
Gleason et al. (121) and let 
 









j (r)  is the mass fraction of constituent  j , which may vary with position,  T  is 
the total (mixture) stress at a point,  T
j





 is the active (contractile) stress borne by constituent  j . The passive response of each 
constituent will be model as an incompressible elastic material; thus,  
 
T
j   p jI  2F j W j C j (F j )T                                           (3.18)  
where we also allow the material to be non-uniform. That is, at each point, each passive 
constituent may be present at a different state of strain (i.e., possess different stress free 
configurations); thus, each constituent can experience different deformations.  




j  0 . Given equation 
3.18, equation 3.17 may be re-written as  
 
T   pI   j öT j
j
 ,                                                        (3.19) 
where                       is the ‘extra’ stress due to the deformation for 
constituent  j  and 
 
p   j p j
j
  is the Lagrange multiplier which arises due to 
incompressibility. Analogous to equation (3.8), the ‘extra’ stress due to the deformation 
for the mixture is          . 
 Let us consider four key structural constituents: elastin, collagen, smooth muscle, 
and water. Let water be modeled as an inviscid fluid; thus  T
w  pwI  (and   
   ). Let 
elastin be modeled as an isotropic material; we employ a neo-Hookean model for elastin,  
 
W e  be(I
1






 is a material parameter. Let muscle be modeled as a transversely isotropic 
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 are material parameters. Again we assume that the fibers do not 









m <1 . Let 

















































the collagen fibers are oriented at angles 0° and  
c
. We neglect the contribution of the 
‘isotropic’ part of equation 3.22 thus,  b
c  0 . That is, we assume that the collagen fibers 
are embedded in the amorphous matrix described by the isotropic terms in equations 3.20 
and 3.21.  
 Kinematics: Non-Uniform Constrained Mixture: The components of  F
j
 and  C
j
 
for inflation and extension are easily calculated as 
 






j       and      
 






j )2 .       (3.23) 











































    (3.24) 
where  (R




n ) j   the axial length of a cylindrical shell for which 
constituent  j  is at zero stress (for this material point);  
(L





cylindrical shell. Thus, in addition to determining material parameters, one must either 
prescribe or experimentally quantify the natural configurations  (R




n ) j  for each 
constituent. One way to prescribe these natural configurations is to assume that each 






 in an in vivo (homeostatic) 
configuration  r  r
h
 and  
h
; given these stretches and this loaded geometry,  (R





n ) j  may be determined via equations 3.24. 
 For collagen ( j  c ), we let the current and natural configurations of each fiber-
family be described in terms of a fiber angle and fiber length. Let  
jk  and  
jk
 be the 
fiber angle of fiber-family  k  of constituent  j  (i.e., collagen) in the current and natural 
configurations, respectively, and let  
jk
 and  
jk
 be the length of each fiber-family  k  of 
constituent  j  in the current and natural configurations, respectively. Thus, instead of 
prescribing the natural configuration in terms of  (R




n ) j , we will prescribe the 
natural configuration in terms of  
jk
 and  
jk
. Let us assume that each fiber  k  of 









 in the in vivo (homeostatic) configuration  r  r
h
 and  
h
. The length of the 
fiber in the in vivo configuration can be calculated as 
 










































.                              (3.25) 











,                                                               (3.26) 
where we emphasize that the reference length of each fiber family will vary with radial 
location. Note, that this fiber will be stress free as long as the length of the fiber equals 
the unloaded length  
jk
; thus, the stress free configuration may be defined at any stress 
free fiber orientation angle  
jk
. Let us define the natural configuration, such that when 
the fiber length is  
jk
, the dimensions of the cylindrical shell passing through  r  r
h
 
with length  
h
 are such that  2(R
n) j  (Ln) j . For this case,  
 











 ,                                                (3.27) 
where each fiber angle in the reference configuration will vary with radial location.  
 Given this natural configuration  (





 and fiber angle 
 
jk




 may be evaluated as 
 
 jk 
 jk cos( jk ( jk ))
for 0   jk  45
2r
 jk sin( jk ( jk ))








  and   
 











Thus, given values for  
ck
 and  
ck
 via equations 3.28, we can evaluate equation 3.22. 
3.2.4. Microstructurally-motivated models: distributions of fibers  
 Microscopy reveals that cells and fibrous matrix constituents, such as collagen, 
exhibit not just a few discrete fiber directions, but rather a continuous distribution of fiber 
directions. Microscopy also reveals significant variations in the undulation collagen 




Thus, we will allow different members of each constituent class to possess different sets 
of natural configurations and describe the distribution of mass over these different sets of 
natural configurations via distribution functions.  
 For elastin and muscle, we adopt the approach of Gleason and Humphrey(130). 
Briefly, we assume that constituent j is present in the in vivo state at a homeostatic 





















j (R, L;r)  that results from laying down new material with the 












j (R, L;r)  be described by a Beta probability distribution function, with independent 


















































































j , and q
L
j
 are shape parameters,  B(,)  is the Beta function,  
R
min
j (r) = 
 R




j (r) = R











 =  L





 are mean values of the natural configurations, and  R
j
 and  L
j
 are the widths of the 
distribution. If we know the current state  (r
h , h ) , we can prescribe the mean natural 

































 We will consider collagen to be comprised of a distribution of fibers with fiber 
orientations   [0,90]  and fiber stretches  

f
. Thus, we let 




    
    
    




        
       
 
   
 
                               (3.31) 
where            describes how the mass of collagen is distributed over all possible 




















cos2() , where   denotes the 
angle between the fiber direction and  Z  axis in the natural configuration,   is the length 
of the fiber in the loaded configuration, and  is the unloaded length of fibers oriented in 
the direction  .  
 We will let the fibers be laid down at a homeostatic distribution of fiber angles 
































































      
(3.32) 



































 will be solved along with material and other 










,;s) . As 
with elastin and smooth muscle, rather than prescribing the distribution of in vivo 
stretches and then mapping these stretches back to a reference state, we will simply 
prescribe the distribution of fiber lengths ( ) in the reference state; let this distribution 
be denoted as  B(,;r) , via a Beta distribution function, as 
( ) 1 ( ) 1
( ) ( ) 1
( ( )) ( ( ) )
B( , )





c c p q




   
 
 
    
       
                     (3.34) 
where we recall that ( ; )s   , ( ) and ( )
j jp q   are shape parameters, ( )max   and 
( )min   are the maximum and minimum values of   (i.e., B( , ) 0    for max   or 
min   ), and ( , )B    is the Beta function. We let  p
j ()  q j ()  = 4.5 and 
  max min =0.10. 
 The distribution of mass over all combinations of fiber angle and fiber stretch 
may be given as 
                                   .                                       (3.35) 
Note that this distribution function has the properties  
                                 and            
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Here, we only consider distribution functions that possess symmetry about the r z  
plane and the r   plane; thus the limits of integration of   = 0 to  /2 in equation 3.31 
represent the first quadrant, which is repeated in the 2
nd





quadrant). In equation 3.22, only symmetry about the r   plane is required. Note, too, 
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 Therefore, from equation 3.22 to equation 3.31, we set the limits of integration of   = 0 
to  /2 and multiply by 2.   
3.2.5 Parameter Estimation 
 Material parameters were determined via a nonlinear regression technique that 
minimized the error between measured values of P  and f  and calculated values of P  
and f  from equations 3.7 and 3.10 given measured values of outer diameter and length 
under these measured values of P  and f ; also unloaded radius, length, and thickness 
where measured. We employ equation 3.1, with equation 3.6, and specify the in vivo 
configuration and transmural strains in this configuration to determine F  and C . We 
seek to identify material parameters via nonlinear regression with the minimization 
function 
 
min_fun  error  penalty(i) 
2
i







































                      (3.39) 
quantifies the difference between experimental data and modeling predictions and 
penalty(i)  is a penalty function that is used to enforce several ‘side conditions’ described 
further below. Calculations were performed in MatLab 7.4 using the lsqnonlin 
subroutine; this subroutine allows the prescription of upper and lower limits on the 




between 0 mN and 40 for the f   tests; taken together, the three P d  tests and three 
f   tests represent n = 800 to 1200 data points.  
3.2.6 Penalty Set 
 The microstructural motivation for proposing a mixture based constitutive 
equations 3.19-3.22 is that each constituent (elastin, collagen, muscle, and water) will be 
‘structurally significant’. By structurally significant, we mean that each contributes 
significantly to the overall biomechanical response. Thus, in addition to minimizing the 
error between experimental data and the model prediction, we also seek a set of 
parameters that represent well the characteristic responses of each constituent. Simply 
identifying the material parameters in equations 3.20-3.22 by minimizing the error 
function 3.39, does not ensure that each constituent will contribute significantly to the 
overall stress. For example, a good fit may occur with eb  very small; thus, the 
contribution of elastin to the overall stress would be negligible. To ensure that each 
constituent is structurally significant, we must impose additional constraints (or penalties) 
on the error function during parameter estimation. We enforce the constraint that, under 
modest pressure, the stress in elastin contributes to at least 30% of the overall stress and 
under high pressure, the stress in the collagen contributes to at least 75% of the overall 
stress. Let us impose the following constraints.  
1. For 59 < P  < 61 mmHg and 1.79 < z  < 1.81, let  
    
                                           (3.40) 
2. For 159 < P < 161 mmHg z  > 1.9, let  
    
           




The first constraint (equation 3.40) ensures that elastin contributes significantly under 
sub-physiological loading. The second constraint (equation 3.41) ensures that 
collagen bears much of the load over supraphysiological loading. These constraints 
may be enforced via the penalty method described below. For example, if the 
pressure and stretch are within the loading range specified and     
          , then 
let
 
                                   
              
where w  is a weighting parameter and i  denotes the ith data point. 
3.2.7 Statistical Analysis 
 Parameters were obtained for each of the models for all of the data sets.  Data sets 
were from 3 groups of 6 vessels with culture stretches of *
z =1.65, 
*
z =1.80, and 
*
z =1.95 
on day 0 and day 2 of culture. Note, the high stretch only had 5 complete data sets.  An 
ANOVA analysis was performed using Minitab to test for differences in parameters 
between the groups both at day 0 and day 2.  Additionally, a repeated measures ANOVA 
was used to investigate changes within each of the three groups between the two time 
points. Statistical differences were reported for p < 0.05. 
3.3 Results 
3.3.1 Chuong and Fung Model 
 The lower and upper limits of parameter values were set at 10[0,10 ]c  and 
[0,10]ic   for 1,...,6i  . The final fitted parameter values were insensitive to initial 
parameter guesses. The mean value of the error was 0.085, which provided a reasonably 









Figure 3.1: The Chuong and Fung phenomenological model fits the data well. 
Nonlinear regression techniques were used to calculate parameters for the Chuong and 
Fung model from the biaxial mechanical data.  The results were then plotted with the 
data to visualize the goodness of fit.   Panel A is from the pressure-diameter tests and 
shows pressure versus outer diameter and axial stretch while B shows axial force 
versus outer diameter and axial stretch from the force-length tests. Open black circles 
represent experimental data and blue x’s represent model predictions.  The fit visually 




 Statistically significant differences were observed between groups cultured at *
z
=1.65 and 
z =1.95 for parameters c , 2c , 4c  and 6c  (Table 3.1). In addition, c  and 2c  
differed across the groups cultured at *
z =1.80 and 
*
z =1.95 and 4c  was different between 
1.65 and 1.80.  Repeated measures ANOVA showed differences all parameters in the *
z
=1.65 culture group between day 0 and day 2 and differences in c , 1c , 2c , 3c  and 5c  for 
the *






Table 3.1: Material parameters for the model of Chuong and Fung determined via non-
linear regression. 
a
 indicates p<0.05 when comparing 1.65 and 1.95 on day 2, 
b
 indicates 
p<0.05 when comparing 1.80 and 1.95 on day 2, 
c
 indicates p<0.05 when comparing 1.65 
and 1.80 on day 2, 
d
 indicates p<0.05 when comparing day0 and day 2 the 1.65 group, 
and 
e
 indicates p<0.05 when comparing day0 and day 2 for the 1.80 group. 
    c (kPa)   c1   c2   c3   c4   c5   c6   error 


























































































































































































































































































































































438 e 0.062 e 0.252 e 0.543 e 0.009 
 






























































































































































































































































































































































237 a,b 0.148 
 
0.373 a,b 1.008 
 
0.000 a 0.086 a 0.141 
 
0.107 
    124.2   0.093   0.200   0.857   0.000   0.126   0.113   0.032 
a Indicates p<0.05 when comparing 1.65 and 1.95 on day 2. 
    b Indicates p<0.05 when comparing 1.8 and 1.95 on day 2. 
    c Indicates p<0.05 when comparing 1.65 and 1.8 on day 2. 
    d Indicates p<0.05 when comparing  day 0 and day 2 for the 1.65 group. 






3.3.2 Four Fiber-Family Model 
 The lower and upper limits of the parameters were 
5
1 and [0,10 ]
kb b  , 
]10,10[ 542
kb , and [5o,85o ] . Final parameter values were insensitive to initial 
guesses. The model provided a good fit to data with a mean value of the error = 0.055 
(Figure 3.2). For all vessels at all culture times the fiber-family model provided a better 
fit than the Fung model (Table 3.2); this finding is consistent with Gleason et al.
 
(131). A 
significant difference was seen for 31b  at day 2 across the low (
*
z =1.65) and high (
*
z
=1.95) stretch culture groups and across day 0 and day 2 for low stretch culture group.  
Additionally, the parameter 22b  is significantly different across day 0 and day 2 for the 
*








Figure 3.2: The Four Fiber-Family Model has a better fit than the Chuong and 
Fung Model. Nonlinear regression techniques were used to calculate parameters for the 
four fiber-family model from the biaxial mechanical data.  The results were then plotted 
with the data to visualize the goodness of fit.   Panel A is from the pressure-diameter tests 
and shows pressure versus outer diameter and axial stretch while B shows axial force 
versus outer diameter and axial stretch from the force-length tests. Open black circles 
represent experimental data and blue x’s represent model predictions.  The fit visually 
looks good and improvement over the Chuong and Fung model was confirmed by an 








Table 3.2: Material parameters for the model of the four-fiber family model determined 
via non-linear regression. 
a
 indicates p<0.05 when comparing 1.65 and 1.95 on day 2, 
b
 
indicates day 0 and day 2 the 1.65 group, 
c
 indicates p<0.05 when comparing day 0 and 
day 2 for the 1.80 group. 
    b (kPa)   b1
1 (kPa)   b2
1   
b1
2 
(kPa)   b2
2   
b1
3 
(kPa)   b2
3   α   error 






















































































































































































































































































































































































































































































































































































































































































































































































































































































SD   8.04   2.13   0.145   9.0   0.029   0.0009   1.466   14.2   0.024 
                   a p<0.05 when comparing 1.65 and 1.95 on day 2 
              b p<0.05 when comparing day 0 and day 2 for group 1.65 
            c p<0.05 when comparing day 0 and day 2 for group 1.80 





3.3.3 Microstructurally-Motivated Models: A Discrete Set of Fibers  
 We considered several variants of the rule of mixtures model, discussed 
separately below. In all cases, we prescribed the lower and upper limits of the parameters 
as be,bm ,b1
m ,b1
c1 , and b1
c2 [0,10 ] , b2
m ,b2
c1  and b2
c2 [105 ,10] , and 
c2
h 5
o,85o  . 
Final parameter values were insensitive to initial guesses. For the models that include 
material non-uniformity, unless otherwise noted, we prescribe the limits 
(Rn )e / Rn[0.8,0.95] , (Ln )e / Ln[0.8,0.95] , (Rn )m / Rn[0.95,1.1] , 




[1.0,1.876] . Note that these limits force elastin to be in 




muscle may be in tension or compression. Rather than tabulating statistical differences in 
parameters for each variation of the rule of mixtures model, we instead present 
parameters from representative vessels from day 0 and day 2 at each culture stretch to 
allow comparison of the different model variations (Table 3.3).  
 ROM A: Uniform Four-Fiber: 1 Muscle Fiber, 3 Collagen Fibers (8 Material 
Parameters, 1 Structural Parameter): Consider the rule of mixtures equations proposed 
above, but assume that the material is uniform; thus, ( )n eR = ( )n cR = ( )n mR =
nR  and ( )n ezL
= ( )n czL = ( )
n m
zL =
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Notice that this model reduces to the four fiber-family model described above; if 
( )e e m mb b b   , 11 1
m mb b , 12 2
mb b , 11
2
1
ccbb  , 12
2
2
cbb  , 21
3
1
ccbb  , and 22
3
2
cbb  , 
then equations 3.43  are identical to equations 3.16, determined from a four fiber-family 
model. If we let  b
e  b (2e)  and  b
m  b (2m) , then the identical fits as above with the 
four fiber-family model will be achieved. The mean error for the four vessels considered 
was 0.055, which was equal to the mean of all vessels for the four fiber-family model; 





Table 3.3: Material parameters representative data for the various versions of the rule-




















cα ωc2 Re Lz
e Rm Lz
m λc error penalty 
Day 0, λz*=1.65 (061604_01) 
ROM A  
(no 
pen) 215 163 165 0.034 96.2 0.107 0.0 1.895 63.2 --   --   --   --   --   0.041 --   
ROM A 380 158 0.0 0.000 59.4 0.152 1.09 0.977 65.6 --   --   --   --   --   0.051 0.002 
ROM B 380 157 0.0 0.008 1983 1.171 102 5.267 65.2 0.96 0.80 1.10 0.99 1.273 0.051 0.002 
ROM C 505 170 0.0 0.000 389 4.331 --   --   60.0 1.00 0.80 1.10 0.95 1.222 0.081 0.006 
Fiber 282 130 45.1 0.000 2345 0.751 240 3.436 64.7 0.92 0.80 1.10 0.95 1.303 0.056 0.002 
Day 2, λz*=1.65 (061604_01) 
ROM A  
(no 
pen) 104 69.3 40.5 0.246 192 0.036 0.1 1.228 35.3 --   --   --   --   --   0.044 --   
ROM A 149 16.7 37.3 0.060 115 0.136 5.4 0.570 49.4 --   --   --   --   --   0.089 0.001 
ROM B 153 28.6 6.7 0.702 288 0.153 8.9 0.438 47.7 1.00 0.80 1.10 1.10 1.876 0.086 0.001 
ROM C 149 0.0 0.0 2.341 59.7 0.361 --   --   36.4 1.00 0.80 1.10 1.09 1.760 0.129 0.006 
Fiber 61.3 12.7 88.9 0.022 1700 0.548 403 0.985 46.8 0.90 0.80 1.10 0.95 1.433 0.101 0.008 
Day 2, λz*=1.80 (100804_02) 
ROM A  
(no 
pen) 37.3 24.3 86.1 0.052 262 0.034 0.4 1.046 27.0 --   --   --   --   --   0.055 --   
ROM A 105 9.2 13.3 0.158 107 0.205 11.5 0.446 37.8 --   --   --   --   --   0.088 0.001 
ROM B 105 35.8 15.2 0.302 337 0.194 12.0 0.401 39.1 1.00 0.81 1.10 1.10 1.876 0.088 0.001 
ROM C 113 0.0 10.5 0.401 59.7 0.361 --   --   36.4 1.00 0.80 1.10 1.09 1.760 0.129 0.006 
Fiber 73.8 2.6 78.0 0.000 1878 0.967 407 1.248 39.8 0.95 0.80 1.10 0.95 1.406 0.113 0.010 
Day 2, λz*=1.95 (052804_02) 
ROM A  
(no 
pen) 137 91.0 29.2 0.117 288 0.097 0.0 1.400 40.2 --   --   --   --   --   0.064 --   
ROM A 134 83.1 0.0 0.000 225 0.153 6.8 0.348 53.3 --   --   --   --   --   0.071 0.000 
ROM B 208 38.3 0.0 0.000 725 0.151 8.3 0.368 55.3 1.00 0.80 1.07 0.95 1.876 0.070 0.000 
ROM C 137 69.6 0.3 0.888 116 0.261 --   --   27.8 0.95 0.80 1.10 0.95 1.783 0.122 0.009 








 We also enforced the constraints 3.40 and 3.41 via the penalty method for this 
rule of mixtures model. The mean value of the error was 0.084 for the four vessels 
considered (Table 3.3), which provided a worse fit than the ROM A without penalties 
(i.e., the four fiber-family model), but equally well as the Fung model; these findings are 
consistent across all vessels. The average penalty for these four vessels was 0.001; thus, 
the penalty criteria were nearly, but not completely, satisfied. Figure 3.3 is a stress-stretch 
plot of individual components as well as the total stress for a representative vessel 
illustrating that the model does indeed capture physiologic loading scenarios which are 





Figure 3.3: The rule-of-mixtures model captures the individual components’ 
physiological contributions of the total stress. The circumferential stress-stretch 
behavior of the each component was calculated and plotted with the resulting graphing 
showing that the components contributed as expected with elastin bearing the majority of 





 ROM B. Non-uniform Four-Fiber: 1 Muscle Fiber, 3 Collagen Fibers (8 Material 
Parameters, 7 Structural Parameter): Next, consider the same functional form of the 
constitutive equation as in (ROM A), but let the material be non-uniform. That is, let 
( ) /n e nR R , ( ) /n m nR R , ( ) /
n e n
zL L , ( ) /
n m n





 , and 2c
h
  be free (structural) 
that may be determined via non-linear regression along with the eight material 
parameters. Note that we set 1c
h






 . First, we let the upper and lower 
limits for the structural parameters of elastin be (Rn )e / Rn[0.8,1.0]  and 
(Ln )e / Ln[0.8,1.0] ; these regressions are referred to as ROM B1. The mean value of the 
error was 0.083 for the four vessels; the average penalty was 0.001. Thus, adding 
material non-uniformity provided little to no increase in the goodness of fit (see Figure 
3.4 A&B). Notice, too, that several of the structural parameters obtained via regression 
were at, or very near, the upper or lower limits prescribed for the regression. Next, we set 
the upper and lower limits for the structural parameters of elastin as 
(Rn )e / Rn[0.8,0.95]  and (Ln )e / Ln[0.8,0.95]  (denoted ROM B2); thus, elastin is 
required to be in tension in the mixture reference state. The mean value of the error 
equaled 0.100 for the four vessels, and the average penalty was 0.002. Thus, by simply 
requiring that elastin be in tension, there was a significant reduction in the goodness of 
fit. Notice, too, that whereas 1
c
h
  was at its upper limit of 1.876 for all four vessels in 
ROM B1, the average value for 1
c
h
  was 1.46 in ROM B2. 
 ROM C. Non-uniform Four-Fiber: 1 Muscle Fiber, 3 Collagen Fibers (6 Material 
Parameters, 6 Structural Parameters): Here we consider the same non-uniform model at 
ROM B, but let 11
cb = 21
cb  and 12
cb = 22












Figure 3.4: Requiring collagen fibers to have the same material properties in all 
orientations decreases the goodness of fit. Nonlinear regression techniques were used 
to calculate parameters for different variations on the rule-of-mixtures models.  The 
results were then plotted with the data to visualize the goodness of fit.  Open black circles 
represent experimental data and blue x’s represent model predictions.   Panels A and B 
show results of the pressure-diameter and force-length tests respectively for ROM B1. 
Panels C and D show the results for the variation ROM C. ROM C is the same as ROM 
B1 except that the material properties of the collagen fibers in the axial and off-axis are 
required to be the same.  This constrain reduces the goodness of fit as observed both 






oriented in the 1c
h
  direction equal those oriented in the 2c
h
  direction. The mean 
value of the error was 0.152 for the four vessels considered, and the average penalty was 
0.006. Thus, requiring the collagen fibers in the axial and off-axis directions to have the 
same material parameters significantly reduced the goodness of fit and satisfaction of the 
penalty criteria (see Figure 3.4 C&D). 
3.3.4 Rule of Mixtures Model: Distributed Fibers 






 , and 2c
h
  be free (structural) parameters that may be determined via non-linear 





cb . We used 
the values from ROM B2 as initial guesses for this fiber distribution. The mean value of 
the error equaled 0.098 for the four vessels, and the average penalty was 0.005.  The 
addition of a distribution of fibers did not appear to greatly change the goodness of fit of 
the model as the error values for the model were similar to ROM B2, which had the same 
number of free parameters. In this analysis, we fixed the width of the distribution 





the elastin and muscle distribution. These parameters, however, could be adjusted to 
improve the goodness of fit. Ultimately, however, the utility of such microstructurally 
motivated model is to quantify the fiber distribution directly from data (c.f., (132, 133)), 
rather than prescribing the fiber distribution functions, as done in this aim.    
3.4 Discussion 
 Mechanotransduction of mechanical signals to cellular responses plays a central 




pathologies. Fundamental to quantifying a mechanosensitive biological response of a cell 
within a tissue is the quantification of the mechanical environment in a local 
neighborhood around that cell. When a good approximation of the local mechanical 
environment (e.g., in terms of stress and strain) is made, only then can a correlation be 
rightfully made between local mechanical stimuli and local biological response. Thus, 
there is a pressing need to better quantify the local mechanical environment in blood 
vessels and how this local mechanical environment evolves as the tissue grows and 
remodels. Towards this end, we have quantified material and structural parameters for 
several constitutive models for mouse carotid arteries exposed to altered axial extension 
in organ culture.  
 We found that the model of Chuong and Fung (122) provided a good fit to data. 
However, motivated by the fact that blood vessels have smooth muscle cells oriented 
circumferentially and collagen fibers oriented axially and distributed at off-axis angles, 
we considered a microstructurally-motivated four fiber-family model. In all cases the four 
fiber model provided a better fit to data than did the model of Chuong and Fung. Indeed, 
even two fiber-family models, with fibers oriented at  , have been shown to provide 
good agreement with data (118). A four fiber-family model has been shown to provide a 
better fit to data from mouse vessels than a two fiber-family and a slightly better fit than a 
three fiber-family model (134), at the cost of additional material parameters. For the sake 
of improving the fit, the cost of additional parameters when using a four fiber-family over 
a two or three fiber-family model may not be well justified. However, when attempting to 
ascribe physical meaning to each fiber-family (e.g., by allowing one fiber-family to 




represent collagen oriented off axis), the number of fiber families should be chosen based 
on observations of the microstructure.  
 Although our goal in considering a four fiber-family model was to ascribe each 
fiber family to a key structural constituent observed via microscopy, we found that 
simply performing non-linear regression did not ensure that each fiber family (i.e., 
structural constituent) contributed significantly to the mechanical response. Rather, it was 
necessary to employ a penalty method to ensure that each constituent had a significant 
contribution.  Since the classic paper by Roach and Burton (127) it has been thought that 
elastin plays a key role in the mechanical behavior over low loads and collagen 
dominates the mechanical behavior over high loads.  Brankov et al. (116) also suggests 
that elastin is under a higher strain in vivo than collagen. Based on these observations, we 
imposed penalties and upper and lower limits on structural parameters that enforced these 
general observations. Although these penalties reduced the goodness of fit compared to 
the non-penalized fits, the overall goodness of fit with the penalties included was, in 
many cases, still equal to the fits obtained via the model of Chuong and Fung; thus, fits 
that required each constituent be structurally significant still produced a model with 
reasonable agreement with data. We also submit that such criteria are critical when 
assigning physical meaning to material and structural parameters.  
 We also found that allowing the stress free states (or homeostatic stretches) of 
each constituent to be structural parameters that are solved via regression did not 
significantly improve model fits. Importantly, however, although this material non-
uniformity did not play a significant role in improving the fit of data to our models, 




quantifying microstructurally motivated models for tissue growth and remodeling (130, 
135, 136).  
 Limitations of the constitutive modeling originate from the adopted assumptions. 
First, we modeled the mouse carotid artery as a homogeneous mixture. It is clear, 
however, that these vessels have a thin intima consisting of an endothelial cell monolayer 
on a basement membrane, a media consisting of smooth muscle, elastin, and collagen, 
and an adventitia dominated by fibroblasts and collagen; thus vessels are heterogeneous. 
Unfortunately, sufficient data is not available on the distribution of the key structural 
constituents and how the content and organization of these constituents evolve during 
remodeling to various changes stimuli. Although these data are not currently available, as 
data becomes available, the structurally motivated models are capable of accounting for 
vessel heterogeneity by incorporating experimentally observable spatial and temporal 
variations in structural parameters. Second, because the opening angle was not measured 
in Gleason et al., which was the data set used for the model development, (120) we 
assumed that the strain was uniform across the wall in the in vivo configuration; this 
assumption may be tested as data on the evolution of opening angle during remodeling 
become available. Third, and more fundamental, is the assumption that the overall stress 
is given as the sum of the stresses borne by the individual constituents in the fiber-family 
and rule of mixtures models, thus, excluding the contribution of constituent-to-constituent 
interactions. Ultimately, incorporation of such interactions will provide important 
insights toward mechano-biology; however, sufficient data are not yet available to 
motivate reasonable functional forms for such constitutive equations. Finally, we model 




motion of the tissue on the whole; this need not be (and likely is not) the case. To 
overcome all of these limitations, there is a need for data that quantifies the spatial and 
temporal variations of constituent content and organization with remodeling and 
mechanical loading.   
 In conclusion, we have identified material (and structural) parameters for 
phenomenological and microstructural models of mouse common carotid arteries 
exposed to altered axial extension, ex vivo. We have identified models with parameters 
that provide good agreement with data, while ascribing physical and microstructural 
meaning to fiber families that are associated with the underlying microstructural content 
and organization of the tissue. Although we made several assumptions (e.g., 
homogeneity, uniform strain in vivo, etc.), as data becomes available these assumptions 
may be relaxed. Through the application of new imaging strategies, experimental 
quantification of spatial and temporal variations in microstructural parameters promises 
to yield models with broader capabilities to predict the evolution of mechanical behavior 







Specific Aim 2: Characterize the mechanical behavior, microstructure, protease 
activity, and ECM gene expression of arteries from an HIV-1 transgenic mouse 
model. 
4.1 Introduction 
 Due to the success of highly active antiretroviral therapy (HAART), HIV 
infection has been transformed from a terminal diagnosis to a manageable chronic 
disease. HIV patients, however, have an elevated incidence of dyslipidemia, 
lipodystrophy, insulin resistance, diabetes mellitus, and cardiovascular disease (CVD); 
the latter includes an elevated risk of myocardial infarction (2-4) and higher prevalence 
of atherosclerotic lesions (5-7), as well as increases in markers of subclinical 
atherosclerosis including increased carotid artery intima-media thickness (8-13), 
increased arterial stiffness (8, 14, 15) and impaired flow-mediated brachial artery 
dilation, an indicator of endothelial dysfunction (8, 9, 14, 16-20).  
 HAART drugs, particularly protease inhibitors (137-141), but also other drug 
classes (16, 142-144), are often implicated as a mediator of early on-set cardiovascular 
disease. Data, however, also suggests that HIV, independent of HAART, can induce 
CVD (9, 13, 145). Specifically, carotid intima-media thickness (c-IMT) and impaired 
flow mediated dilation (FMD) have been observed in HIV positive, HAART naïve 
patients (9).  Similarly, exposure of endothelial cells in vitro to various HIV proteins 
decreases nitric oxide synthase, increases cell adhesion molecules, endothelial 
permeability, cell proliferation, cytokine signals, apoptosis, and oxidative stress (81, 84, 




there remains a need to investigate the effect of the viral proteins, independent of viral 
infection and HAART, on the vasculature in an in vivo model.  
 The purpose of this aim is to characterize the effect of HIV proteins on 
mechanical behavior, microstructure, protease activity, and ECM gene expression of 
arteries using an HIV-1 transgenic mouse model. The NL4-3Δ gag/pol transgenic mouse 
(HIV-Tg) is a non-infectious model with a 7.4 kb transgene that contains the genetic 
sequence for the HIV-1 proteins env, tat, nef, rev, vif, vpr, and vpu, but lacks the gag and 
pol genes and is thus unable to replicate (146). The clinical markers of atherosclerosis, 
arterial stiffening and thickening, will be measured through biaxial mechanical tests, 
histology, and confocal imaging.  Additional markers of vascular remodeling quantified 
were collagen and elastin content and cathepsin activity. Vascular remodeling due to 
synthesis, proteolytic degradation, and remodeling of key structural components of the 
arterial wall (e.g., elastin and collagen) lead to changes the biomechanical properties of 
the artery (e.g., arterial stiffness). Specifically, ECM content differs in healthy and 
atherosclerotic vessels and the cathepsins family of proteases is unregulated in diseased 
vessels as well. (147-149).  
4.2 Methods 
4.2.1 HIV-Transgenic Mouse Model 
 The NL4-3Δ gag/pol transgenic mouse strain was used. 10-12 week old male 
hemizygous and wild-type littermates (FVB/N) were used. Homozygous HIV-1 Tg mice 
are smaller at birth, have decreased food intake compared to wild-type mice, and usually 
die within 40 days postnatal; thus, homozygous mice were not included in this study 




specifically renal failure known as HIV-associated nephropathy (146). All animals work 
was conducted under the regulation of Georgia Institute of Technology’s and Atlanta VA 
Medical Center’s Institutional Animal Care and Use Committee (IACUC). 
4.2.2 Common Carotid Artery and Aorta Preparation 
 Mice were euthanized with CO2 and the right and left common carotids arteries 
and the aorta were removed. Briefly, the ventral side of the mouse was cleaned with 
alcohol and an incision was made from the groin to jaw. Tissue was dissected and 
removed to expose both common carotid arteries and the aorta from the aortic arch to the 
iliac bifurcation. Right and left common carotid arteries and the aorta were excised and 
cleaned free of any remaining perivascular tissue.  
4.2.3 Biomechanical Measurements: Cylindrical Biaxial Testing, Arterial Stiffness, 
and Opening Angle 
 Cylindrical Biaxial Testing: Cylindrical biaxial biomechanical tests of the arteries 
were performed as previously described to characterize the biomechanical behavior of 
these arteries (150). During the experiment the excised common carotid arteries and 
aortas were maintained in culture medium [Dulbecco’s modified Eagles medium 
(DMEM, Invitrogen, Inc.) containing 4.5g/L glucose and sodium pyruvate and without L-
glutamine and phenol red]. For the aorta, branches within the suprarenal region were 
ligated using 10-0 silk sutures, and 8-0 suture was used to mount the arteries on two glass 
cannulae on a custom biaxial mechanical testing device (150). The vessel and cannulae 
were suspended in a bath on the device, which was filled with media containing sodium 
nitroprusside (SNP) to ensure that the arteries were fully dilated during the mechanical 




the luminal pressure. The mounting cannulae are attached to computer controlled 
actuators that allow for precise control of the vessel length and a force transducer vessel 
during testing. Thus, this computer-controlled device has the capability of maintaining 
precise luminal pressure and axial length of the vessel, while recording the outer diameter 
and axial force during the testing.  
 Following preconditioning, fixed length pressure-diameter tests and fixed 
pressure force-length tests were performed under quasistatic loading conditions (150).  
During the pressure-diameter tests, vessels were inflated to 160 mmHg at a series of fixed 
axial stretches of  λ=1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9 (λ is the loaded vessel 
length/unloaded vessel length), with three loading/unloading cycles for each axial stretch. 
During the force-length tests the vessels were held at constant pressures of 0, 40, 60, 80, 
100, and 120 mmHg and stretched to an axial load of 1 gram (for common carotid 
arteries) or 3 grams (for the aorta) with three loading/unloading cycles at each pressure.  
 Arterial Stiffness: The Peterson’s modulus (  ), a common measure of arterial 
stiffness, was calculated as the slope of the pressure-outer diameter curve (Δ  Δ   at a 
given pressure normalized to the outer diameter ( ) at that pressure; namely,    
Δ   Δ    . 
 Opening Angles: Following testing or microscopy imaging (described below), 
ring sectors were cut from the arteries to obtain their stress free configuration. Opening 
angle measurements were taken to quantify the residual stress in the unloaded 
configuration (151). A 14% gelatin mixture was injected into the vessel and allowed to 
solidify. Then the artery was cut into a series of segments and placed in phosphate 




and the open sectors were allowed to equilibrate for 30 minutes. A dissection microscope 
and camera were used to take pictures of the cross-section of the sectors and an image 
processing script in MatLab (MathWorks) was used to find the vessel wall area A, inner 
arc length Li, and outer arc length Lo. The opening angle can then be calculated using the 
following equations.  
                 (4.1) 
Note, that θ is the half of the central angle of the stress free sector; thus, the traditional 
opening angle is 180 – θ (151). 
4.2.4  Intima-Media Thickness Measurements  
 The vessel wall thickness was quantified by two methods: confocal imaging of 
live arteries mounted on the biomechanical testing device was used to quantify the 
intima-media thickness and adventitia thickness, and standard histology of fixed, 
sectioned, and stained vessels was used as an additional measure to quantify intima-
media thickness.  
 Confocal Microscopy:  The custom biomechanical testing device fits on a LSM 
510 META inverted confocal microscope (Zeiss) to visualize the microstructure across 
the entire wall of live, unfixed mouse arteries (150). Collagen and elastin were imaged 
using their autofluorescent properties. The isolated vessel, maintained in PBS, was 
excited with a 800 nm two-photon laser, collagen was visualized by detecting its second 
harmonic generation around 400 nm, and elastin emissions were detected by setting the 
META filter to a 480-560 nm bandpass configuration (153). Using the device, z-stacks 
were collected at a variety of loading conditions including physiologic pressure and 












the adventitial layer (collagen images) and intima-media layer (elastin images) of the 
arteries.  Note that while the media is thought to contain some collagen, the amount and 
fibrils in the mouse media is too small to detect using the established confocal methods; 
thus the images containing only collagen or only elastin are considered to be the adventia 
and media layers respectively.       
 Histology: Vessels were fixed in their unloaded state in 10% buffered formalin, 
immersed in 30% sucrose overnight, embedded in optimal cutting temperature medium, 
and frozen. The arteries were cut into 7 μm thick slices, mounted on slides, and stained 
with hematoxylin and eosin. The images were analyzed using ImageJ (NIH) to quantify 
the thickness of the arteries.  
4.2.5 Other Microstructure Analysis  
 Collagen Fiber Analysis: The confocal microscopy images were also used to 
quantify the angular distribution of fibers within the arterial wall.  The angles of fibers in 
each slice of the z-stack were quantified using a fast Fourier series algorithm program in 
a MATLAB script as established previously. (154-156)  Briefly, the initial processing 
included a low-pass filter, conversion to binary, and windowing with a 2D Tukey 
window.  A fast Fourier transform of the preprocessed image generated a power 
spectrum.  A histogram of the frequency of intensities between -90 and 90 degrees with 4 
degree bins was created from the spectrum.  This process was repeated for each slice 
within the z-stack to generate a distribution of fibers across the wall for each vessel.  The 
thickness and relative wall location were normalized and the corresponding distributions 
in each vessel were averaged to create a surface which represented the fiber angle 




 Quantification of elastin breaks: Additional slides were prepared using the same 
protocols for the histological thickness measurements.  These slides were stained with 
Verhoeff-Van Gieson elastin stain, which specifically stains the elastin fibers black.  The 
Verhoeff-Van Gieson slides were used to quantify potential elastin breaks in the lamellae 
4.2.6 Collagen and Elastin Content Measurements 
 Pairs of carotid arteries from a single mouse or a single suprarenal aorta were 
dried in a vacuum oven at 37
o
C for 2 days. The dry weight of the vessels was recorded 
for normalizing to protein content. In the samples for collagen analysis, the collagen was 
solublized by placing the vessel in 0.5 mL of 0.5 M acetic acid containing pepsin in a 1:3 
ratio of enzyme to tissue weight. The tubes containing the vessels were placed in a 37
o
C 
water bath for 48 hours with occasional agitation. Sirius red dye solution (0.3 mg/mL 
direct 80 Sirius red in 0.5 M acetic acid) was added to each tube and the solution was 
incubated at room temperature for 30 min. The supernatant was removed following 
centrifuging, and 0.1 M HCl was added, and the sample was centrifuged again. Finally, 
0.5 M NaOH was added and the samples were votexed to release the dye. The collagen 
content was then determined by measuring the absorbance of each sample at a 
wavelength of 540 nm.  
 The elastin content of the arteries was quantified using the Fastin Elastin Assay 
(Biocolor). First, elastin from the dried arteries was solublized by boiling in 0.25 M 
oxalic acid for 5 hours. Elastin in the sample solutions was then precipitated using the 
manufacturer’s precipitating agent. After 10 minutes the samples were centrifuged, and 
the supernatant was removed. The Fastin dye solution was then added to the tubes and 




centrifuged again, and the unbound dye in the supernatant was removed. A dye 
dissociating solution was added to release the dye from the walls of the tube. The 
absorbance at 513 nm of the resulting solution was used to quantify the elastin content of 
the arteries.     
4.2.7 Cathepsin Expression and Activity Measurements 
 Gelatin zymography: Cathepsin activity was quantified by gelatin zymography. 
Excised suprarenal aortas or two pairs of carotids (4 arteries) were stored on ice and place 
in 50 ul of lysis buffer (20 nM Tris–HCl [pH 7.5], 5 mM ethyleneglycoltetraacetic acid 
[EGTA], 150 mM NaCl, 20 mM β-glycerol phosphate, 10 mM NaF, 1 mM sodium 
orthovanadate, 1% Triton X-100, and 0.1% Tween 20) with 0.1 mM leupeptin freshly 
added to stabilize enzymes during electrophoresis. The arteries were homogenized using 
disposable sample grinders (GE Healthcare), and protein concentrations were obtained by 
the bisinchoninic acid (BCA) assay (Pierce). Cathepsin zymography was performed as 
described previously (157, 158). 5X non-reducing loading buffer (0.05% bromophenol 
blue, 10% SDS, 1.5 M Tris, 50% glycerol) was added to all samples prior to loading. 
Equal amounts of protein were resolved by 12.5% SDS-polyacrylamide gels containing 
0.2% gelatin at 4°C. Gels were removed and enzymes renatured in 65 mM Tris buffer, 
pH 7.4 with 20% glycerol for 3 washes at 10 minutes each. Gels were then incubated in 
activity buffer (0.1 M sodium phosphate buffer, pH 6.0, 1 mM EDTA, and 2 mM DTT 
freshly added) for 30 minutes at room temperature. Then this activity buffer was 
exchanged for fresh activity buffer and incubated for 18-24 hours (overnight) incubation 
at 37°C.  The gels were rinsed twice with deionized water and incubated for one hour in 




destaining (10% isopropanol and 10% acetic acid ). Gels were scanned using an 
Imagequant 4010 (GE Healthcare).  Images were inverted in Adobe Photoshop and 
densitometry performed using Scion Image (Scion Corporation).  
4.2.8 Statistical Analysis 
 All data presented is mean plus or minus standard error mean (±SEM). Means 
between groups were compared using unpaired student t tests with significance at p < 
0.05. All statistics were performed in either Excel (Microsoft) or GraphPad Prism 
(GraphPad software). 
4.2 Results 
4.2.1 Mice expressing HIV proteins exhibit increased arterial stiffness and altered 
biomechanics 
 Cylindrical biaxial biomechanical testing revealed that the common carotid 
arteries from the HIV Tg mice have a smaller diameter for a given pressure, with 
statistically significant differences at pressures between 60 and 100 mm Hg (p<0.05) for 
the in vivo axial stretch of λ=1.7 (Figure 4.1 A) and subphysiological stretch of λ=1.4 as 
well (Figure A.1 in appendix). No differences were observed in aortic diameters (Figure 
4.1 C). Peterson’s modulus, a common measure of arterial stiffness, revealed that the 
HIV Tg arteries exhibited elevated arterial stiffness, compared to wildtype arteries. 
Statistical differences were seen at pressures for common carotid arteries at the in vivo 
axial stretch (λ=1.7; Figure 4.1 B), as well as at subphysiological (λ=1.4) and 
superhysiological (λ=1.9) stretches (Figure A.2 in appendix). Similarly, statistical 




axial stretch  (λ=1.7) (Figure 4.1 D), and at subphysiological (λ=1.4) and 
superphysiological (λ=1.9) stretches (Figure A.3 in appendix).    
 No differences were observed in the axial force during fixed length pressure-
diameter tests over physiologically-relevant loads; significant differences were observed 





Figure 4.1: HIV-1 protein expression increases arterial stiffness. Mechanical testing 
was used to investigate the biomechanics of carotid arteries (A, B) and aortas (C, D). 
Pressure-diameter mechanical tests (A & C) were performed at a series of fixed stretches. 
Peterson’s modulus, Ep, of the vessels  was used to normalize for differences in vessel 

























































































































Figure 4.2: HIV-1 protein expression results in increased opening angle and 
circumferential residual stress. The residual stress within the vessel wall was calculated 
by measuring the opening angle of radially cut ring sectors of the arteries (A). The graph 
indicates the HIV Tg mice have a greater opening angle and thus more residual stress 
than the wildtype mice in both the suprarenal aorta and carotid arteries. (B)  (* indicates p 


































observed in the in vivo axial stretch across groups. There was no significant difference in 
the axial force-length behavior of the vessels over physiologically relevant loads; for the 
carotids significant differences in the axial force length response were observed at the 
low stretches and low pressures (Figure A.4 B in appendix). No significant differences in 
the axial behavior of the aortas were observed at any loading conditions.  Both the 
carotids and suprarenal aortas from HIV Tg mice had larger opening angles compared 
vessels from wildtype mice (Figure 4.2). The increased opening angle in the HIV Tg 
mice indicated there was a greater residual stress  
in the vessel wall in the unloaded state, which suggests that cells within wall have 
remodeled as an adaption to changes to maintain local stress in the loaded state. 
4.2.2 Mice expressing HIV proteins have increased carotid intima-media thickness 
 HIV Tg mice showed increased intima-media thickness compared to control mice, 
confirmed by both the histological and confocal microscopy methods (Figure 4.4). 
Confocal microscopy images of the arteries in their physiological state (pressure=100 
mmHg and λ=1.7) (Figure 4.3) revealed an increased medial thickness in the HIV Tg 
mice for both the suprarenal aorta and carotids.  Additionally, the carotids in the HIV Tg 
mice had advential thickening. (Figure 4.4 A) Histological slides stained with H&E also 
showed intima-media thickening in the HIV Tg mice for both vessels in their unloaded 
state (Figure 4.4 B).   Note that the values of mean intima-media thicknesses measured 
from the confocal images were smaller than the values measured with histology as the 
confocal measurements were collected in a physiological (loaded) state in which the 









Figure 4.3: Confocal images can be used to quantify thickness and collagen fiber 
distribution. Confocal microscopy techniques were used to collect z-stacks of the 





Figure 4.4: HIV-1 protein expression increases intima-media thickness. Thickness of 
the arteries was calculated using cross-sectional views from confocal microscopy stacks 
of collagen and elastin autofluorescence and histology cross-sections.    Panel A shows 
the thickness values calculated from cross-sectional views of confocal microscopy image 
stacks of the arteries under a physiological load (pressure=100 mmHg and λ=1.7). The 
intima-media thickness in the HIV Tg mice was increased for both arteries, and the 
carotids also had an advential thickening.  Panel B shows the intima-media thickness 
calculated from fixed/frozen histological slides stained with H&E and thickness was 














































































4.2.3 Collagen Fiber Angles are similar between groups 
 The distribution of the collagen fiber angles in the adventia was also quantified as 
collagen fibers contribute significantly to the mechanical behavior of the arterial wall and 
changes in orientation could possibly play a role in describing differences in that 
behavior.  Thus a fiber angle distribution was calculated using fast Fourier transform 
techniques for each image in the confocal microscopy z-stacks. These distributions were 
used to create surfaces of the fiber angle distribution through the wall as shown in figure 
4.5 A.  The average of the distributions through the wall was calculated (figure 4.5 B) but 
the weighted mean fiber angles for the vessels (a measure of the peak) showed no 
significant differences in distribution (figure 4.5 C). 
4.2.4 Elastin breaks 
 A set of histological slides were stained with Verhoeff-Van Gieson stain which 
stained the elastin fibers black.  The slides were then inspected for breaks in the elastic 











Figure 4.5: Collagen fiber angles no major differences. The distribution of collagen 
fibers within the advential was determined using fast Fourier transform techniques on 
images from the confocal microscopy z-stacks. Panel A shows a representative surface 
plot of the distribution through the wall for HIV Tg aorta group.  Panel B shows the 
average distributions across the wall for the carotids and aortas.  Panel C plots the 
weighted mean fiber angles which shows no statistically significant  differences are 

































4.2.5 Aortas from mice expressing HIV proteins have lower elastin content 
 The normalized elastin content of the suprarenal aortas and carotids was 
determined using the Fastin assay (Biocolor).  The HIV Tg aorta had significantly less 
elastin than the wildtype (HIV Tg = 0.21 μg elastin/ μg dry tissue and wildtype= 0.13 μg 
elastin/ μg dry tissue).    The elastin content of the carotids was not significantly different  
but had values of 0.32 and 0.37 μg elastin/ μg dry tissue  for HIV Tg and wildtype 
respectively (p=0.21 n=9). (Figure 4.6 A)  Collagen content was also assessed using Sirus 
red staining as shown in Figure 4.6 B. The HIV Tg mice had a non-significant trend of 
more collagen for both the aorta and carotids (p=0.069 n=6 and p=0.18 n=5 respectively). 
The decrease in elastin content and trend in increased collagen content aligns well with 
the finding that vessels from HIV Tg have increased arterial stiffening.   
4.2.6 Aorta from mice over-expressing HIV proteins exhibit increased cathepsin K 
and S activity. 
 Cathepsins K, S, and V are potent elastases. Zymographic analysis of 
homogenized carotids from HIV-Tg and wildtype mice show an almost 2.5 fold increase 
in the activity of cathepsin S (n=3 p<0.05).  Cathepsin V, however, decreased in the HIV 
Tg carotids as compared to the wildtype controls (n=5 p<0.05) (Figure 4.7). These results 
are in agreement with similar results by my collaborators who found increases in 
cathepsin K and S as well as the decrease in cathepsin V in the HIV Tg suprarenal aortas  
(Figure A.5 in appendix). Increased proteolytic activity by cathepsins supports the 
finding of decreased elastin in the HIV Tg arteries. While this decrease in elastin in only 
significant in the aortas, the method used to quantify elastin determines with the total 








Figure 4.6: HIV-1 protein expression decreases elastin content. Elastin and collagen 
content of the arteries was assessed using the Fastin and Sirius red assays.  (A) Aortas 
from the HIV Tg mice had less elastin than the wildtype mice but the observed decreased 
elastin content from the common carotid arteries was not significant (p=0.21 n=9). (B) 
Similarly a non-significant trend of increased collagen in the HIV Tg mice was found for 
collagen for both the aorta and carotids (p=0.18 n=5). (* indicates p<0.05, # indicates 















































































Figure 4.7: Carotids from mice HIV Tg mice have increased cathepsin S and 
decreased cathepsin V activity. Cathepsin activity in the arterial wall was determined 
using zymography and densitometry to quantify the changes.  A representative 
zymography gel is shown in panel A.  More pronounced white bands indicate increased 
cathepsin S activity in HIV-Tg mice. The results of the densitometry used to quantify the 
zymography bands show an increase in cathepsin S activity in the HIV Tg carotids, but a 
decrease in cathepsin V. (B) (* indicates p < 0.05 N=5 (N=3 for cathepsin S and L) and 












































degrading the elastin but the protein has not yet been removed from the tissue and the 
assay lacks the sensitivity to detect very small changes.  
4.4 Discussion 
 Clinical data clearly show endothelial dysfunction (8, 9, 14, 19, 20), increased 
arterial stiffness (8, 77, 137, 159-161), and increased c-IMT (8-13) in HIV patients, 
which have been attributed both to HAART treatment and HIV infection (162). This aim 
corroborates these findings in HIV-Tg mice, suggesting that HIV-1 proteins alone, 
independent of HAART treatment or HIV infection, may play a role in cellular and tissue 
level remodeling associated with atherosclerosis.  
 Lorenz et al., suggest that HIV-1and HAART are independent mediators of 
carotid intima-media thickening. These studies found that the intima-media thickness of 
the carotid bifurcation was 24.8% higher in HIV-1 positive/HAART-naïve patients 
compared to uninfected controls, but they observed significantly greater intima-media 
thickness of the carotid bifurcation and the common carotid artery due to HAART 
treatment in HIV-1 positive subjects, compared to HIV-positive / HAART naïve subjects 
(163). Arteries from the HIV-1 Tg mouse exhibited increased intima-media thickness.  
Additionally, we did find an increase in adventitial thickness in the HIV Tg carotids as 
well, though this is not a clinically measurable parameter. These findings indicate that 
HIV-1 proteins alone may play a role in cellular and tissue level remodeling associated 
with atherosclerosis.  
 Arterial stiffening is an important clinical marker of cardiovascular disease; 
indeed, arterial stiffening is a key predictor of future cardiovascular events (164). 




arteries, and pulse wave analysis and pulse wave velocity studies suggested elevated 
aortic stiffness from HIV-1 patients regardless of HAART treatment (8, 77, 137, 159-
161). Rigorous mechanical tests on aorta and common carotid arteries from the HIV-TG 
and wild-type mice revealed that arteries were stiffer in HIV-Tg mice, indicating the HIV 
proteins alone may play a role in the increased stiffness that is observed clinically. 
Although HIV-associated immune dysfunction is known to play a role in atherosclerotic 
development (165) and has been associated with arterial stiffness in HIV-infected 
subjects (159), this mouse model lacks infected immune cells; however, the results 
suggest that changes in response to the proteins themselves may mediate the arterial 
stiffening in this mouse model through mechanisms that are yet to be determined. 
 In addition to corroborating clinical observations in HIV-patient populations and 
isolating the role of a single mediator (e.g., HIV proteins) on disease progression, one of 
the key advantages of animal models is the ability to collect measurements that cannot be 
obtained from human subjects. Biomechanical analysis revealed several important 
findings that are not experimentally tractable in patients. First, although differences were 
observed in the circumferential mechanical response of arteries, there were few 
mechanical differences in the axial direction. Also, observed differences in the opening 
angle suggest differences in the local, in vivo mechanical environment (i.e., the local 
stresses) under physiological loads at different locations across the vessel wall. Such 
differences in the local circumferential mechanical environment may provide insights 
into local differences in mechanically-mediated biological responses.  
 Vascular remodeling occurs in part by synthesis, proteolytic degradation, and 




and changes in vascular functional (e.g., endothelial dysfunction), which can lead to 
changes geometric, and biomechanical properties of the artery (e.g., c-IMT, and arterial 
stiffness, respectively). While the differences in collagen were not statistically 
significant, aortas from HIV Tg mice had significantly less elastin. Loss of functional 
elastin is often attributed with arterial stiffening and is common with aging, aneurysm 
development, and atherosclerosis (166, 167). Thus, the observed decrease in elastin 
supports the observed increases in arterial stiffness in HIV-Tg mice.  
 Upregulation of the cysteine cathepsin family of proteases in humans and mouse 
models of atherosclerosis are known to play a key role in vascular remodeling (147-149); 
cathepsin activity is upregulated in atheroprone regions of the vasculature (168). 
Zymography revealed cathepsin S activity in the arterial wall was increased two-and-a-
half-fold in the presence of HIV proteins. These changes in cathepsin levels (Figure 4.7) 
may occur as the result of impaired nitric oxide production and bioavailability and/or pro-
inflammatory viral proteins, thereby increasing elastolytic activity and degrading elastin 
in the arterial wall (Figure 4.6), leading to maladaptive remodeling that increases arterial 
stiffness (Figure 4.1), opening angle (Figure 4.2), and c-IMT (Figure 4.3).  
 This aim presents observational results that expression of HIV proteins leads to 
geometric, functional, and biomechanical changes that are consistent with clinical 
observations in HIV populations. The mechanisms by which HIV proteins lead to such 
changes, however, remain unknown. HIV-1 has not been shown to infect vascular 
endothelial cells in vivo; however, it is postulated that in HIV-infected populations 
endothelial dysfunction may be caused by exposure to circulating infected CD4+ T cells 




85). The tat protein, which is actively secreted by infected cells, has been found to have a 
variety of negative effects on the vasculature. Namely, tat has been shown to decrease the 
ability of pig coronary arteries to dilate by the inhibiting the expression of nitric oxide 
synthase (NOS) and thus nitric oxide availability (84). Exposure of endothelial cells to tat 
also causes them to release monocyte chemoattractant protein-1 (MCP-1), which 
increases adhesion to the endothelium and transendothelial migration of circulating 
mononuclear cells into the vascular wall (85). Numerous other studies have found various 
other effects of tat, gp120, vpu, and nef proteins on endothelial cells including expression 
of several cell adhesion molecules, increasing endothelial permeability, cell proliferation, 
cytokine signals, apoptosis, and oxidative stress (81).  In this study, a transgenic mouse 
model (NL4-3Δ gag/pol) was employed to investigate the effects of HIV proteins and 
while a non-infectious mouse model, the mice have a similar phenotype to the altered 
signaling and function that has been observed in vascular endothelial cells exposed to 
HIV-1 proteins. 
 While there are compelling arguments to suggest that the observed vascular 
changes may be a direct result of HIV-1 proteins on vascular cells, there are also 
compelling arguments to suggest that these observations are a secondary effect of other 
systemic changes, such as end-stage organ disease, dyslipidemia, hypertension, and/or 
inflammation. For example, Kopp et al. reported that the NL4-3Δ gag/pol transgenic 
hemizygous mice develop proteinuria by 4 weeks of age and end-stage renal disease by 
14 weeks (Kopp et al 1992). Such renal disease and associated hypertension could lead to 
some of the observed vascular changes reported here. Given that such secondary 




underlying mechanisms are a direct affect of HIV-1 proteins or a downstream affect of 
other systemic changes) this model captures many of the salient features of HIV-
associated cardiovascular disease and provides a platform to study the underlying 
mechanisms of HIV-1 protein mediated mechanisms of atherosclerosis. 
In summary, the HIV-Tg mice did exhibit several characteristics that are 
indicative of preclinical atherosclerosis. The HIV-Tg mouse model offers the advantage 
of isolating the effects of the viral proteins not possible clinically. While data from 
clinical studies have found that HIV-1 positive patients exhibit early markers of 
atherosclerosis, some discrepancies still exist between studies due the inability to control 
other cardiovascular risk factors such as age, gender, weight, cholesterol levels, smoking, 
and hypertension in all patients as well the confounding effects from HAART therapy.  
This study isolates the in vivo effects of the HIV-1 proteins without these confounding 
factors. Whereas in vitro studies have observed some effects such as endothelial 
dysfunction and monocyte adhesion (81, 84-86), those in vitro models do not allow for 
the study of clinically observed characteristics such as arterial stiffening and thickening. 
These findings support the further use of this animal model to study mechanisms 





Specific Aim 3: Characterize the mechanical behavior, microstructure, protease 
activity, and ECM gene expression of arteries from wild type mice given the 
antiretroviral medication AZT. 
 
5.1 Introduction 
 The development and widespread use of HAART has increased the life 
expectancy of HIV patients in recent years.  However, the drugs have been implicated in 
the early on-set and increased risk of numerous co-morbidities, including cancers, 
pulmonary disease, renal disease, hepatic disease, diabetes, and cardiovascular disease. 
The latter includes increased myocardial infarction (65, 66, 169) and atherosclerotic 
lesions (67, 170).  Additionally, an increase in a number of preclinical signs of 
atherosclerosis including increased carotid intima-media thickness (c-IMT) (8, 72, 171), 
arterial stiffening (8, 78, 79), and impaired flow mediated dilation (FMD), an indicator of 
endothelial dysfunction (78, 90, 91) is seen in HIV patients on HAART.     
 The role of specific HAART drugs in these symptoms remains unclear. While 
some studies have suggested that viral infection itself plays a significant role (73, 76, 
172), many studies have implicated HAART as playing a significant role in 
atherosclerotic development (87, 88). Specifically, the nucleoside reverse transcriptase 
inhibitors (NRTIs), which include azidothymidine (AZT), and protease inhibitors (PIs) 
have been shown to cause changes that might be implicated in endothelial dysfunction. 
(81, 173)  These two classes of drugs have widespread use and are included in most 




(66, 174) Herbert et al. found that AZT caused significant decreases in cellular 
respiration, a marker for mitochondrial activity.(95)  Administration of the drugs also 
increased cell death in endothelial cells and increased vascular smooth cells replication, 
both of which disturb healthy vascular function. Another study with AZT found that 
treatment of healthy mice with AZT for 35 days reduced the endothelial-dependent 
dilation of the aorta when exposed to acetylcholine. Additionally, the vessels had 
significantly increased superoxide levels. (96)  
 The purpose of this aim was to investigate the effects of AZT treatment on 
arteries from healthy mice specifically with respect to the other subclinical markers such 
as arterial stiffening and intima-media thickening.  The use of a healthy mouse model in 
the study allowed us to isolate the effects of a specific HAART drug on the artery without 
the influence of the HIV virus or the confounding factors in human studies, while also 
allowing us to investigate tissue level changes to the vasculature (structure and 
mechanical behavior) not studied in the previous in vitro studies. Potential arterial 
stiffening and overall mechanical behavior of the vessels was determined with cylindrical 
biaxial mechanical tests and opening angle measurements.  Changes to the vessel 
geometry and microstructure, including intima-media and adventitia thickness, collagen 
fiber angle distribution, and elastin breakage were determined via confocal microscopy 
and histology. We also quantified of collagen and elastin content and measured protease 
activity (specifically cathepsins) through zymography. Additional, physiological factors 







5.2.1 Animal Model 
  The animal model used for this study was healthy adult male FVB/N mice 
(Jackson Labs) (FVB/N is also the background strain of the mice in aim 2).  The HAART 
drug selected for the study was AZT (azidothymidine), which is one of the common 
NRTIs. AZT was administered via oral gavage for 35 days at a dosage of 100 mg/kg 
AZT in 0.25mL water.  The control mice were given 0.25 mL of water via oral gavage 
for 35 days.  Treatment was initiated at 5 weeks of age and thus the average age of the 
mice at the end point was 10-11 weeks as with the previous aim.  
5.2.2 Blood Pressure Measurements 
 The blood pressure of the mice was monitored periodically throughout the time 
course of the treatment.  Columbus Instrument’s non-invasive blood pressure monitoring 
system was used to record the blood pressure and heart rate via a tail cuff system. The 
testing methods were followed as prescribed in the user’s manual.  To obtain accurate 
blood pressure measurements and acclimate mice to the restrainer chamber, mice were 
placed in the chamber for 30 minutes once a day for 3 days prior to actually collecting the 
data.  The chamber was provided with the system and is a clear plastic tube with an 
adjustable endcap with a hole for the tail that was adjusted to fit snuggly over the base of 
the tail preventing movement of the mouse.  This is necessary because the tail must be 
held still in the sensor and occlusion cuff for accurate and noise-free measurements. To 
collect the data, the sensor and occlusion cuffs were threaded on the tail and positioned as 
close to the base as possible.  Once restrained the heating unit was placed above the 




temp of 37-39 degrees Celsius.  Heating was done to improve blood flow in the tail but 
once the temperature was reached, the heating unit was turned off for the actual data 
collection. Once the tail was preheated, data was collected by starting a continuous scan, 
which inflated the occlusion and sensor cuffs to collect systolic, diastolic, and mean 
blood pressure as well as heart rate. Each collection cycle was repeated for 20 minutes 
and the average values of measurements were used for analysis.  Blood pressure 
measurements were taken at the start of treatment, 2.5 weeks after treatment initiation, 
and 5 week after treatment initiation, just before the end of the treatment.  
5.2.3 Common Carotid Artery and Aorta Preparation 
 At the end of 35 days of treatment mice were euthanized with an intraperitoneal 
injection of sodium pentobarbital. Prior to opening of the chest cavity blood was 
collected via cardiac puncture.  Briefly a 26 gauge needle was inserted at approximately a 
30
o
 angle just below the sternum, and the plunger was slowly withdrawn to collect 0.5-
0.8 mL of blood.  Following blood collection, the chest and abdomen were opened and 
both common carotids arteries and the aorta were removed and cleaned as in aim 2.  
5.2.4 Lipid Studies 
 The blood collected via cardiac puncture was immediately transferred to heparin 
coated tubes and centrifuged to separate the components.  The plasma was removed and 
frozen for analysis of the blood lipid levels specifically cholesterol and triglycerides.  The 
cholesterol levels were determined using an assay kit from Abnova, which detects both 
cholesteryl esters and free cholesterol by hydrolyzing the esters with the included esterase 
enzyme. The cholesterol is then oxidized and the resulting hydrogen peroxide is detected 




peroxidase to produce a detectable fluorescent compound.  Briefly, a 1:400 diluted 
plasma sample in the assay buffer was pipetted into a 96 well plate and the assay cocktail 
mixture was added.  The assay cocktail included assay buffer, the cholesterol detector 
(ADHP)), horseradish peroxidase, cholesterol oxidase, and cholesterol esterase.  The 
plate was then covered and incubated for 30 minutes and the cholesterol was detected 
using fluorescence with excitation wavelengths between 530-580 nm and emission from 
585-595 nm.  
 Plasma triglyceride levels were determined using a colorimetric kit by Abnova.  
Briefly, the samples were pipette into a 96 well plate with the provided assay buffer.  
Lipase was added to the wells and incubated for 20 minutes at room temperature to 
convert all of the triglycerides to glycerol and fatty acids.  Next, a reaction mix of assay 
buffer, a triglyceride probe, and a triglyceride enzyme mix was added to the wells and 
incubated for 30-60 minutes. Following, incubation the plate was read for absorbance at 
570 nm.   
5.2.5 Biomechanical Measurements: Cylindrical Biaxial Testing, Arterial Stiffness, 
and Opening Angle 
 Cylindrical Biaxial Testing: As in aim 2, cylindrical biaxial biomechanical tests of 
the arteries were performed as previously described to characterize the biomechanical 
behavior of these arteries (150). Briefly, the cleaned arteries were cannulated on our 
custom built device and following preconditioning both pressure-diameter and force-
length testing protocols were performed.   
 Arterial Stiffness: The Peterson’s modulus (  ), a common measure of arterial 




given pressure normalized to the outer diameter ( ) at that pressure; namely,    
Δ   Δ    . 
 Opening Angles: Following testing or microscopy imaging (described below), 
ring sectors were cut from the arteries to obtain their stress free configuration. Opening 
angle measurements were taken to quantify the residual stress in the unloaded 
configuration following the same procedures described in aim 2.  
5.2.6 Intima-Media Thickness Measurements  
 The vessel wall thickness was quantified by two methods: confocal imaging of 
live arteries mounted on the biomechanical testing device was used to quantify the 
intima-media thickness and adventitia thickness, and standard histology of fixed, 
sectioned, and stained vessels was used as an additional measure to quantify intima-
media thickness.  
 Confocal Microscopy:  The custom biomechanical testing device fits on a LSM 
510 META inverted confocal microscope (Zeiss) to visualize the microstructure across 
the entire wall of live, unfixed mouse arteries (150). Collagen and elastin were imaged 
using their autofluorescent properties as described in aim 2.  
 Histology: The same histological methods as aim 2 were employed with vessels 
were fixed in their unloaded state, frozen for sectioning, and stained with hematoxylin 
and eosin. The images were analyzed using ImageJ (NIH) to quantify the thickness of the 
arteries.  
5.2.7 Other Microstructure Analysis  
 Collagen Fiber Analysis: The confocal microscopy images were also used to 




transform method described in aim 2.  The thickness and relative wall location were 
normalized and the corresponding distributions in each vessel were averaged to create a 
surface which represented the fiber angle distributions through the wall for both groups.  
 Elastin breaks visualization:   As in aim 2, slides were prepared using the same 
protocols for the histological thickness measurements.  These slides were stained with 
Verhoeff-Van Gieson elastin stain to quantify potential elastin breaks. 
 5.2.8 Collagen and Elastin Content Measurements 
 The Fastin assay (Biocolor) and Sirius red assay were used to quantify the elastin 
and collagen content of the dried arteries using the same methodology more thoroughly 
explained in aim 2.   The extract proteins for were measured on a plate reader and the 
values were normalized to the tissue dry weight for analysis. 
5.2.9 Cathepsin Expression and Activity Measurements 
 Gelatin zymography was used to quantify the activity of cathepsins in the arterial 
walls.  As in aim 2, the tissues (1 aorta or 2 pairs of carotids) were homogenized, protein 
concentration was determined and the samples were loaded in a SDS-page gel containing 
gelatin and were separated using electrophoresis.  The enzymes were then renatured and 
activated using a series of buffers, and gels were stained for detection of the bands which 
remain light. Gels were then scanned and densitometry was performed to quantify 
activity.  
5.2.11 Statistical Analysis 
 All data presented is mean plus or minus standard error mean (±SEM). Means 




0.05. All statistics were performed in either Excel (Microsoft) or GraphPad Prism 
(GraphPad software). 
5.3 Results 
5.3.1 Mice treated with AZT do not have increased blood pressure 
 Blood pressure was monitored at three time points (beginning, middle, and end) 
throughout the study using a tail-cuff measurement system.  The results showed no 
difference in the diastolic or systolic blood pressure between the groups at both the start 
and end of treatment (Figure 5.1).  A slight increase was observed with time but this is 
expected as the mice aged from 5 to 10 weeks.   
5.3.2 Lipid profiles did not differ between treatment groups 
 At the end of the 35 days of treatment blood was collect from the mice and the 
plasma was used to analyze the lipid profiles in the mice.  No detectable differences in 
cholesterol and triglyceride levels were found between the mice (Figure 5.2). 
5.3.3 Mice treated with AZT exhibit increased arterial stiffness and altered 
biomechanics 
 Cylindrical biaxial tests revealed that treatment with AZT causes arterial 
stiffening. Figure 5.3 (A & C) show that the AZT diameter-pressure curve for the in vivo 
stretch (λ=1.7) is shifted downward, meaning that for a given pressure the arteries from 
the AZT treated mice distended less.  The carotids were significantly different at 
pressures of 10-60 mmHg (N=6, p<0.05) while the aortas had statistically significant 
differences at 50-70 mmHg (N=8, p<0.05).  Additionally, the aortas for the AZT mice 
were significantly smaller at pressures of 10-90 mmHg at a subphysiological stretch 








Figure 5.1 Blood pressure does not differ between groups.  The blood pressure of the 
mice was determined using a tail-cuff blood pressure system.  Both the diastolic (A) and 
systolic (B) pressures were measured at the initiation of treatment, 2.5 weeks after 
treatment initiation, and 5 weeks after the initiation of treatment (end of treatment). No 





Figure 5.2 AZT treatment did not alter lipid profiles. Plasma lipid profiles were 
performed on blood collected from the mice at the end of the treatment.  Specifically, 
cholesterol and triglyceride concentrations were quantified; however, no difference was 












































































































stiffness, was calculated as the slope of the pressure-outer diameter curve (ΔP/ΔD) at a 
given pressure normalized to the outer diameter (D) at that pressure; namely, 
Ep=ΔP/(ΔD/D). Modulus results for the aorta showed an increased modulus for the AZT 
treated mice with statistically significant differences at pressures between 10-40 mmHg 
at the in vivo stretch (Figure 5.3 D) and 30- 60 mmHg at a subphysiological stretch 
(Figure B.2 in appendix).  As with the mechanics results in chapter 4 (Figure 4.1), some 
of these statistically significant differences occur at pressures lower than physiological 
blood pressures.  We hypothesize that differences at these slightly subphysiological 
pressure are due to removal of perivascular support when the arteries are excised from the 
mice, which would allow them to expand to diameter larger than those seen in vivo and 
we further hypothesize that the diameters at which the statistically significant differences 
occur are closer those experiences in the body while the pressures are lower in the 
constrained mechanical tests. Current studies in our lab have suggested this is the case for 
porcine coronaries but the hypothesis has not been tested in mice.  
 Axial force was also monitored during the pressure-diameter tests to study the 
pressure-force relationship.  Analysis revealed that the AZT treated aortas had lower 
axial forces at pressure from 10-80 mmHg at the in vivo stretch and a subphysiological 
stretch and 10-70 mmHg at a superphysiological stretch (Figure 5.4) (N=8, p<0.05).  
Additionally, the axial behavior in the force-length tests does not have any major 







Figure 5.3: AZT treatment increases arterial stiffness. Mechanical testing was used to 
investigate the biomechanics of carotid arteries (A, B) and aortas (C, D). Pressure-
diameter mechanical tests (A & C) were performed at a series of fixed stretches. 
Peterson’s modulus, Ep, of the vessels  was used to normalize for differences in vessel 























































































































 Opening angle, an indicator of residual stress, was also quantified though no 





Figure 5.4: AZT treatment decreases axial force during pressure-diameter tests. 
Axial force was also measured during the pressure-diameter mechanical tests. Analysis of 
the axial force revealed that the AZT treated mice had significantly lower forces at 
pressures from 10-80 mmHg for the subphysiological and physiological stretch and from 
10-70 mmHg for the superphysiological stretch. (■ is physiological stretch, ▲ is 
subphysiological stretch, and ● is superphysiological stretch,  * indicates p < 0.05, N=9, 






























Figure 5.5: AZT treatment did not result in opening angle differences. The residual 
stress within the vessel wall was calculated by measuring the opening angle of radially 
cut ring sectors of the arteries. The graph indicates the AZT treated mice and water mice 
have the same opening angle and thus the treatment did not result in changes in residual 




5.3.4 Mice treated with AZT have increased carotid intima-media thickness 
 The wall thickness of both arteries was quantified using two different methods. 
Confocal microscopy techniques were used to quantify both the intima-media (elastin 
images) and adventia (collagen images) of the arteries in a physiological state (pressure = 
100 mmHg and axial stretch λ=1.7).  The z-stacks of images showed increased media 
thickness (aorta N=6 p<0.05) while advential thickness decreased (N=6, p<0.05) (Figure 
5.6 A). The increase in intima-media thickness was also confirmed with the histological 
measurements from fixed and frozen unloaded vessels, see Figure 5.6 B.  (N=6, p<0.05) 































Figure 5.6: AZT treatment increased intima-media thickness. Thickness of the 
arteries was calculated using cross-sectional views from confocal microscopy stacks of 
arteries under a physiological load and histology cross-sections. (A) The intima-media 
thickness in the AZT treated mice increased in the aorta, but the adventia was decreased 
in both the aortas and carotids.  (B) The intima-media thickness calculated from 
fixed/frozen histological slides stained with H&E also showed intima-media thickening 




histological techniques are slightly different, this discrepancy could be partially due to 
confocal measurements being taken at a loaded configuration and the histology is 
unloaded as well as processing to the histological samples. 
5.3.5 Collagen fiber distributions are similar between groups 
 The confocal microscopy z-stacks were also used to quantify the angles of the 
collagen fibers in the physiological state.  A fast Fourier transform routine produced a 
fiber distribution of collagen throughout the arterial wall.  The normalized average of the 





















































































Figure 5.7: Collagen fiber angles no significant differences. The distribution of 
collagen fibers within the adventia was determined using fast Fourier transform 
techniques on images from the confocal microscopy z-stacks.  Plots of the average 
distributions across the wall are shown in A for the carotids and B for the aortas.) The 
mean angle from each vessel was also calculated and no differences were found between 
groups (C). (N=6, data is mean +/- SEM, p<0.05) 




































each groups’ distribution and no differences between the arteries from the AZT and water 
treated mice were observed (Figure 4.6 C) (N=6).  
5.3.6 Elastin breaks 
 Histological slides were also stained with Verhoeff-Van Gieson elastin stain to 
better visualize the elastin.  Inspection of the slides revealed intact elastic lamellae and no 
elastin breaks.  
5.3.7 Carotids from AZT treated mice have lower elastin content 
 The protein content of the major ECM components of the arteries was quantified 
for both the AZT and water treated mice.  The Fastin assay (Biocolor) was used to 
quantify elastin content and the results showed a decrease in elastin for the carotids (N=6 
p<0.05) (Figure 5.8 A). Note that the elastin content of the aortas is rather low (we woul 
expect it to be the same or greater than the carotids) but this could possibly be due to 
incomplete extraction of the elastin as the same extraction procedure was performed on 
both the carotids and the aortas.  However, following the same procedure in chapter 4 we 
we were able to detect differences in the aortas (though the values are similar) while we 
did not see differences in the elastin values of the aortas in this chapter.  The results of 
the collagen content assay (Figure 5.8 B) show no difference between the AZT treated 
and water treated mice. 
 5.2.8 Arteries from mice treated with AZT have differences in cathepsin activity. 
 Cathepsins are a family of proteases with potent elastolytic and collagenase 
activity. Gelatin zymography was used to determine the cathepsin activity within the 
aortic and carotid walls.  Densitometric analysis of the gels showed changes in expression 





Figure 5.8: AZT treatment decreases elastin content. Elastin and collagen content of 
the arteries was assessed using the Fastin and Sirius red assays.  (A) The carotids from 
AZT treated mice had less elastin than the water control mice. (* indicates p<0.05, N=6, 
and data is mean +/- SEM). (B) No difference in the collagen content of the arteries was 
observed. (N=6, and data is mean +/- SEM) 






































































Figure 5.9: Arteries from mice treated with AZT have increased cathepsin L and 
decreased cathepsin V activity. The level of activity of cathepsin V, S, and L was 
assessed using zymography.  (A)  Densitometric analysis of the carotids revealed in an 
increase in cathepsin L, while analysis of the aortas showed decreases in cathepsin V 










































































AZT mice had over a 5-fold increase in cathepsin L activity compared the control mice 
(Figure 5.9 A).  Additionally, in the aortas the cathepsin V activity in the AZT was 
decreased in comparison to the control mice (Figure 5.9 B).   
5.4 Discussion 
 While clinical data has shown that patients with HIV-1 are more prone to 
atherosclerosis (66, 87, 88) and exhibit preclinical signs including endothelial 
dysfunction (78, 91), arterial stiffening (8, 78, 79), and increased intima-media thickness 
(8, 72, 75) and in vitro studies have shown that antiretroviral drugs specifically AZT have 
negative effects on vascular cells (95, 96) , the unique roles of the medication and virus 
remains unclear. This study investigated these effects using a mouse model to isolate the 
role of the antiretroviral drugs.  In agreement with the clinical data we found the mice 
had both arterial stiffening and increased thickness.  Additionally, we further investigated 
the structural changes occurring and found decreases in elastin mass fraction and changes 
in cathepsin activity both which supports the findings proatherogenic remodeling. 
 A study by van Vonderen et al. indicates that antiretroviral treatment may play a 
role in mechanical changes to the arteries (77).  The study found significant decreases in 
femoral artery distensibility and compliance between ART-naïve and ART-exposed 
patients.   Similarly, Charakida et al. also saw differences between treated and non-
treated children with HIV with the treated group having a higher pulse wave velocity, a 
clinical measure of arterial stiffness. (175) In our study we saw similar results with mice 
treated with AZT having smaller diameter for a given pressure and a higher Peterson’s 




arterial stiffening that we are able to rigorously quantify with our biaxial mechanical 
tests.    
 Increased carotid intima-media thickness (cIMT) is also a marker of subclinical 
atherosclerosis that has been observed in HIV positive patients.  Lorenz et al. found that 
HIV positive patients had increased cIMT as compared to control patients matched for 
traditional risk factors, but also that HAART treated patients had a 24.8% larger value for 
the carotid bifurcation intima-media thickness than the HAART naïve patients.(70)   The 
larger effect of HAART therapy in bifurcation region of the carotid is significant as this 
is the region most prone to atherosclerotic lesion formation. Additionally, the study found 
that NRTIs (such as AZT) had significant effects on the cIMT specifically with the 
carotid bifurcation 48.1% or 28% higher in patients who had been on an NRTI for less 
than 1 year or more than 2 years respectively as compared to patients who had never 
received an NRTI. As with arterial stiffening, our studies also showed increased intima-
media thickness (IMT) in the AZT mice as compared to the control group (Figure 5.6).  
This finding was confirmed both with histological preparation of unloaded vessels and 
confocal microscopy of vessels in their loaded physiological state.  The confocal images 
also let us quantify advential thickness, a parameter that is not able to be determined 
clinically.  Interestingly, we observed advential thinning in the AZT mice for both the 
aortas and carotids.  This change is the opposite of the advential thickening observed in 
aim 2 in the HIV Tg mice, indicating that while both the viral proteins and AZT have the 
same overall (and clinically observable effects) or arterial stiffening and  intima-media 




 The use of a mouse model to study the effects of AZT allowed us to not only 
isolate the drug from the influence of HIV infection or other lifestyle and risk factors 
present in clinical studies, but we also were able to study a number of parameters that are 
not clinically tractable.  Beyond analyzing the circumferential behavior, where we found 
arterial stiffening as observed clinically, our rigorous mechanical testing protocols also 
investigated the axial behavior.  While carotids did not exhibit changes in axial behavior, 
the aortas from the AZT treated mice had lower axial forces at both in vivo and 
subphysiological stretches at pressures from 10-70 and 10-80 mmHg respectively (Figure 
5.4).   Differences in axial behavior are interesting to note since we know that vessels to 
respond to changes in axial loads. (103, 176, 177)  Another mechanical property we 
characterized that cannot be determined clinically is opening angle as a measure of 
residual stress.  Interestingly, we did not see differences in the opening angles between 
the two groups (Figure 5.5), indicating the vessels were able to maintain the same 
distribution of residual stress despite undergoing remodeling that resulted in changes in 
circumferential stiffness and intima-media thickness.   
 The vascular remodeling, which is responsible for the observed stiffening and 
thickening, is a complex process which involves both the synthesis and degradation of 
key ECM proteins specifically collagen and elastin. In our studies we found a decrease in 
elastin content in the carotids from the AZT treated mice (Figure 5.8). This decrease in 
elastin content is in agreement with the observed arterial stiffening.  Additionally, loss of 
functional elastin is associated with a number of vascular diseases specifically aging, 
aneurysm development, and atherosclerosis. (166, 167)  Zymography was used to 




cathepsin regulation have been associated with atherosclerosis.   Cathepsins are potent 
elastases and collagenases and thus their activity can lead to degradation of the proteins 
within the wall and ECM remodeling.  The observed upregulation of cathepsin L (Figure 
5.9 A) in the carotids is in good agreement with literature where cathepsins were detected 
in atherosclerotic lesions (168). Additionally, we found a decrease in cathepsin V activity 
in the aortas, which we also saw in the HIV Tg mice in aim 1 (Figure 5.9 B and Figure 
4.6).  The reason for this downregulation is not clear from the literature but the 
observation in both the HIV Tg and AZT mice indicates that same sort of conserved 
signaling mechanism is causing this dysregulation of cathepsin activity.  The effects of 
this decrease and possible mechanisms responsible merit further studies.  However, the 
result does seem in-line with preliminary data collected by others in the lab analyzing 
cathepsin activity from monocytes in the blood of HIV patients, which seems to point to 
antiretroviral therapy potentially decreasing cathepsin activity.   
 In summary, the antiretroviral drug AZT (an NRTI) has a number proatherogenic 
effects on the vasculature including arterial stiffening and carotid intima-media 
thickening.  While a number of antiretroviral drugs including NRTIs have been 
implicated in leading to the development of atherosclerosis (70, 76), determining the 
specific role that the medications or a specific medication plays in disease development is 
difficult since many patients have a number of confounding risk factors.  Thus this aim 
used a mouse model to determine the isolated effects of AZT on otherwise healthy mice.  
We found that the mice did indeed exhibit the subclinical markers of atherosclerosis 
observed in patients, and additionally, we were able to study other changes that are not 




quantity, and protease activity.  Thus, the model serves as a good foundation for future 
studies to further investigate the AZT mitigated changes as well as to begin to investigate 






SUMMARY, LIMITATIONS, AND FUTURE CONSIDERATIONS 
6.1 Summary 
 The overall objective of this project was to characterize the mechanical behavior 
of murine arteries through the development of constitutive models that incorporate 
microstructure and a number of experimentally tractable parameters as well as to employ 
mouse models to characterize preclinical markers of atherosclerosis induced by HIV or 
antiretroviral drugs.  While clinical data supported the hypotheses that both the virus and 
HAART drugs have proatherogenic effects, there still remained a need to isolate the 
effects of each in a controlled manner; thus this work used murine models to separately 
study the effects of the viral proteins or antiretroviral drug AZT on the arteries. The 
primary focus was on mechanical and structural changes specifically investigating 
stiffening and thickening, two subclinical markers of atherosclerosis.   
 The constituents that constitute arteries (e.g., collagen, elastin, smooth muscle 
cells), along with their geometry and applied loads, determine the local mechanical 
environment in which cells, the mediators of growth and remodeling, live. It is clear that 
cell-mediated tissue growth and remodeling occurs in response to changes in their local 
mechanical environment and, conversely, changes in microstructural content and 
organization, geometry, and applied loads change the local mechanical environment, 
thereby initiating tissue growth and remodeling. For example in Aims 2 and 3, we 
observed significant changes in the content and organization of collagen and elastin, in 
parallel with significant changes in geometry and the biomechanical response of common 




AZT. The goal of Aim 1 was to develop microstructurally based constitutive models that 
integrate changes at the microstructural level with changes at the tissue level to describe 
and predict arterial behavior.  We showed that the rule-of-mixtures models based on 
constrained mixture theory simulated the mechanical responses as good as 
phenomenological models and the implementation of the penalties ensured the 
constituent each had significant physiological contributions.  Finally, the models 
developed in aim 1 will be able to incorporate some of the structural parameters from the 
last two aims in future work.   
 Aim 2 investigated the role of HIV proteins using a transgenic mouse model in 
which the mice contained transgene for the HIV-1 proteins env, tat, nef, rev, vif, vpr, and 
vpu. The effects of AZT, a NRTI antiretroviral, were studied in aim 3 by administering 
the drug to healthy mice via oral gavage.  In both aims, we observed increased 
circumferential arterial stiffness in both the aortas and carotids for the HIV Tg and AZT 
treated mice.  Similarly, both the HIV Tg and AZT treated mice had increased intima-
media thickening as determined by both histology and confocal imaging.  Thus, we 
conclude that both the HIV viral proteins and the antiretroviral AZT may contribute to 
the development of cardiovascular disease in patients as evidenced by the observed 
subclinical markers of atherosclerosis.   
 The use of an animal model allowed to us to further investigate the arterial 
changes to study aspects not clinically quantifiable. The biaxial mechanical tests included 
force measurements in addition to the pressure-diameter relations that were used to 
observe arterial stiffening.  No differences were found in the axial behavior of the HIV 




The aortas from the AZT treated mice in aim 3, however, did have differing axial 
behavior with the AZT mice having decreased axial forces at pressures of up to 80 
mmHg during the pressure-diameter inflation tests. Additional, mechanics measurements 
also included quantifying residual stress by determining the opening angles of the 
vessels.  The HIV Tg mice had greater opening angles than their wildtype littermates 
indicating greater residual stress, while the opening angles of the AZT mice were not 
different than the water control mice indicating residual stress was maintained during the 
arterial remodeling for that treatment.   
 In addition to the intima-media thickening, the confocal imaging techniques used 
in aims 2 and 3 allowed the quantification of the advential thickness as well.  
Interestingly we observed adventitial thickening in HIV Tg mice as compared to their 
controls while the adventia in the AZT mice was decreased compared to the control 
group.  Thus, while the same clinically tractable trait of intima-media thickening was 
observed in both groups, the adventitial behavior was quite different.  The confocal 
images of the collagen were also used to generate a distribution of fiber angles 
throughout the wall though no statically significant differences were observed in either of 
the two studies.   
 Vascular remodeling occurs as a result of the production and degradation of the 
proteins within the ECM which is comprised mainly of elastin and collagen.  Thus upon 
observing remodeling at the mechanical and tissue structural level, we investigated the 
protein level changes in both aims 2 and 3 through the quantification of the collagen and 
elastin content as well as the protease activity.  In both the HIV Tg and AZT treated mice 




by both stimuli.  In the AZT mice the collagen content was not different than the control 
mice; however, in the HIV Tg mice there was a trend (albeit not significant at p<0.05) of 
increased collagen.  This finding is particularly interesting as we also observed an 
increase in the advential thickness in these mice while the AZT mice had thinning.   
 Proteolytic degradation of the ECM components plays an important role in the 
vascular remodeling.  This study focused on the cathepsin family of proteases, which 
have been implicated in atherosclerosis.  In both aims 2 and 3 we saw changes in the 
activity levels of various proteins.  In aim 2, we observed increases in cathepsin S activity 
and decreases in cathepsin V activity in the HIV Tg mice.  While in aim 3, we observed 
increases in cathepsin L and once again decreases in cathepsin V.  Thus while stimuli for 
the vascular changes are very different (viral proteins vs. an antiretroviral drug), protein 
level changes of decreased elastin and decreases cathepsin V activity are conserved.  In 
general, the results from aims 2 and 3 showed the both HIV proteins and AZT have 
proatherogenic effects and likely contribute to cardiovascular disease in HIV patients.   
6.2 Limitations 
 While the incorporation of microstructure in the constitutive models in aim 
1improves upon previous work by providing more physical meaning to the parameters 
and allowing actual microstructural data to be incorporated into the model, the work of 
aim 1 does have a number of limitations due to various assumptions adopted when 
creating the models.  First, the models assume a homogeneous mixture of the components 
(elastin, muscle, and collagen) throughout the wall, though we know that the arterial wall 
is composed of three distinct layers- intima, media, and adventia- with unique 




collagen and the media is concentric layers of smooth muscle cells and elastin with some 
collagen.  The model however assumes these components are evenly distributed 
throughout the wall, but in the future as more data on the structural distribution is 
collected (i.e. collagen fiber angle distributions as in Aim 2 and 3) a heterogeneous model 
can be developed. Another fundamental assumption of the study was the use of a rule-of-
mixtures approach which constrains the constituents must deform together and follow the 
motion of the tissue as a whole, though is not likely always entirely true.  Additionally, 
the total stress of the vessel is modeled as the sum of the stresses of each individual 
constituent neglecting any interactions between constituents that may contribute to stress. 
It is very likely that the constituents do interact in ways that modulate stress, and as more 
mechanobiology studies quantify these interactions future work can incorporate them into 
the models.  In general, since the model was developed prior to aims 2 and 3, the specific 
assumption of a homogeneous distribution within the wall limits the application of this 
model to the arteries studied in the last two aims as it is unable to incorporate the 
differential changes in layer thickness observed.  While parameters could still be 
determined for these vessels, any conclusions drawn from the parameter values would be 
limited since they do not account for some of the known structural differences.    
 While the experimental work in the last two aims of this dissertation has provided 
many interesting insights into the isolated effects of HIV proteins and AZT on the arterial 
wall specifically demonstrating the clinically observed changes of arterial stiffening and 
increased intima-media thickening, the studies does have a number of limitations that 
must be kept in mind when drawing conclusions from the data.  First, the mouse model 




since it binds to the CD4 complex on the cell surface into order to enter the cells.  The 
specificity of the virus makes infectious animal models difficult. Thus while the 
transgenic mouse used in aim 2 is non-infectious, it models the exposure of the vascular 
cells to viral proteins such as those circulating in the blood or released in by macrophages 
in the arterial wall.  However, quantification of the levels of protein production (and thus 
exposure) in the vascular walls or blood of these mice would determine the exposure 
levels to the arteries.  Bruggeman et al. showed that the transgene was expressed in high 
levels in muscle (likely skeletal muscle cells not vascular SMCs were used) but did not 
directly investigate arteries. (178)  Additionally, the effects of HIV on the arteries are 
also thought to be associated with an inflammatory response causes by prolonged chronic 
infection by the virus.  Thus, patients may have changes in immune cell counts and 
activation levels as well as higher levels of certain circulating cytokines and other 
inflammatory markers both of which are known to have negative effects on the 
vasculature. (72, 90) For example, circulating monocytes, one of the cell types that may 
be infected with the HIV virus in patients, are known to play an important role 
atherosclerotic plaque development through their adhesion and migration though the wall 
where they differentiate into macrophages and eventually foam cells.  HIV infection and 
proteins activate the monocytes making them more susceptible to increased adhesion in 
addition to activating endothelial cells to express adhesion factors. (85, 86, 179)  
Histological analysis of the arteries in aim 2 however shows no evidence of monocyte 
adhesion or migration, thus indicating that the mouse model may not be replicating these 




 Another limitation was that the blood pressure of the HIV Tg mice in aim 2 was 
not measured during the study.  However, Kopp et al. showed that the HIV Tg mice 
developed renal dysfunction and failure, which are both associated with hypertension, 
during a similar time course used in our study. (146) Therefore, there is a possibility that 
the HIV Tg mice might be  hypertensive and the observed vascular remodeling may be 
response to that change rather than a direct effect of the proteins on the arterial wall.  
Currently, we are further evaluating the blood pressure and kidney function of the mice 
and comparison studies should be performed on the same transgenic model bred on a 
different background, which may have less pronounced changes in blood pressure and 
kidney function.  However, regardless of whether the mechanisms behind the vascular 
changes we observed were due to direct effects of the viral proteins on vascular cells or 
systemic changes, the HIV Tg mice did have atherogenic changes due to the addition the 
viral proteins to otherwise healthy mice which implicates the virus’s role the 
development of cardiovascular disease. 
 Aim 3 also had a number of limitations as well.  First we only took the study out 
to 35 days, which is much shorter than both the duration that humans receive 
antiretroviral drugs as well the development of atherosclerosis in humans.  However, a 
study by Shanker et al. showed endothelial dysfunction in only 4 weeks in healthy, HIV 
negative patients who were received the antiretroviral indinavir daily for that period, 
which is inline the time course of our study (91).  Mice also have an accelerated normal 
lifespan compared to humans, reaching maturity around 6 weeks and living only a few 
years, making the time course of the study appropriate. Additionally, the dosage of AZT 




mice have a much higher metabolic rate compared to humans, a higher dosage is 
appropriate; specifically, the half life of AZT in the plasma of mice around 5 times less 
than that of humans (180).  Additionally, the dosage and time course was previously 
published and thus our methods are in line with current work. (96, 181)    
 While our mice did exhibit subclinical markers of atherosclerosis in both of the 
second and third aims, the mice did not fully develop atherosclerosis and had no lesions.  
While we feel that the changes we observed were likely part of the disease development 
rather than some sort of healthy, adaptive remodeling, the observance of the accelerated 
development of actual atherosclerotic lesions would be insightful.  Observing these 
changes, however, would likely require a change in the diet or mouse strain or both or 
much longer time course.  Future work may include this, but the current work still 
revealed a number of pro-atherogenic changes in the mice while the control mice 
remained healthy.    
 Additionally, aim 3 only looked at one class of the antiretroviral drugs.  Thus care 
should be taken to not over-generalize the results of the study to other drug class.  
However, NRTIs are included in almost all HAART regimens and have been implicated 
in CVD, which is why we focused this study on that class.  Another possible limitation is 
that AZT in not commonly used in the United States today; however, the drug is still 
widely used in developing countries and thus still merits study. Careful, consideration 
must be given to discern whether the observed changes are specific to AZT or have wider 






6.3 Future Considerations 
 While the results of this dissertation are interesting in themselves, they also serve 
as a starting point for many more future studies.  First, while the model developed in aim 
1 does capture the microstructural behavior of the arteries, most of the structural 
measures and parameters are assumed or fit.  However, using some of the techniques in 
the last two aims several of these structural measures could be measured and incorporated 
including collagen and elastin content and opening angles.  Additionally, recent work in 
our lab has incorporated the average collagen fiber angles from the confocal images into 
the fiber distribution model. (156) Future models could take this one step further by 
implementing the different distributions throughout the arterial wall rather than an 
average distribution for the entire wall.  Besides incorporating the differing collagen fiber 
angle distributions across the wall thickness, future models could also incorporate 
differing elastin and smooth muscle contents as well to create a more accurate 
heterozygous model of the wall.  This heterozygous model would allow us to incorporate 
the changes we saw in the layer thickness (as determined by elastin and collagen confocal 
images) into the model and therefore determine more accurate and insightful parameters 
for the arteries in aims 2 and 3.  A better understanding of the local stresses within the 
wall from a more accurate model could provide insight to help shape future experimental 
studies as well.  
 The agreement with clinical data, specifically arterial stiffening and thickening, 
helps to establish the two mouse models in aims 2 and 3 as good models for further study.  
Thus while this study focused mainly on several tissue level changes, the agreement with 




One area that merits further investigation is smooth muscle cells. While we 
acknowledged that the primary structural components of muscle are collagen, elastin, and 
smooth muscle, the work focused primarily on the proteins, collagen and elastin. 
However, we know that smooth muscle cells play an important role in the arterial wall 
beyond structure and mechanics but in cell signaling and vascular remodeling as well.  
Specifically smooth muscle proliferation (e.g., intimal hyperplasia) is known to play a 
key role in the development of atherosclerosis (31, 165).  Since the media layer is 
composed primarily of elastin and smooth muscle cells, the decrease in the elastin content 
but increase in intima-media thickness suggests that the increase in thickness might be 
attributed in part to increases in smooth muscle cell volume (not quantified). Further 
work should investigate changes to the smooth muscle cells in the tissue.  A more careful 
histological analysis of smooth cells volume as a percentage of the total arterial wall will 
determine if there is an increase in smooth muscle cells. To determine if any changed are 
due to either proliferation versus hypertrophy, one possible study is measuring BrdU 
uptake in cells to determine if there are changes in smooth muscle cell proliferation in the 
HIV Tg or AZT treated mice.  
 While our studies observed some changes in cathepsin activity, the decrease in 
cathepsin V is a unique finding that merits further study.  Previous studies have found 
that cathepsin S and K were found in the fibrous cap, foam cells, and adjacent to SMCs in 
atherosclerotic vessels (37, 38).   Additionally, stimulation of smooth muscles cells with 
various cytokines induced cathepsin S production and degradation of elastin, and 
cathepsin S-deficient monocytes are not able to migrate through membranes containing 




studies with upregulation of cathepsin S and L; however, we also saw a decrease in 
cathepsin V in both the HIV Tg mice and AZT mice.  This results is interesting since it 
appears to be counterintuitive compared to the current literature.  However, some 
preliminary work by our lab investigating cathepsin activity in white blood cells in blood 
from patients on ART seems to support a decrease in cathepsin activity. Nevertheless, far 
less information on cathepsin V and atherosclerosis exists in literature, and thus this area 
deserves further investigation. Possible studies include in vitro work to try to determine 
the signaling mechanisms responsible for the changes in cathepsin V expression as well 
as the effects that decreased cathepsin V is having on the vascular cells. In addition to 
cathepsins, quantification of other proteases associated with atherosclerosis, specifically 
MMPs, would provide insight into the proteolytic remodeling in the arteries. These 
further investigations of the protease activity may provide insight into possible 
therapeutics to mitigate the effects of the HIV proteins and AZT. 
 Also, now that we have shown that the viral proteins and AZT have significant 
effects on the vasculature that lead to arterial stiffening and thickening, returning to in 
vitro cell work to investigate the signaling pathways and mechanisms might be useful to 
more closely investigate some of the changes observed in our mouse studies including 
cathepsin upregulation and changes in gene expression of various ECM proteins.  Once 
more specific pathways for these changes have been determined the mouse models could 
be used as models to test potential therapeutics to try to either mitigate some of the 
negative effects of AZT (or other drugs) or prevent harm induced by the viral proteins.  
 Both the HIV Tg and AZT treated mice developed vascular changes consistent 




not focus on capturing a number of other characteristics of HIV patients that may be 
associated with the development of the observed vascular remodeling.  Specifically, HIV 
patients are known to have systemic chronic inflammation as evidenced by increases in a 
number of cytokines and inflammatory markers in the plasma.  Future work could 
quantify these markers such as those in a study by Calmy et al. in the plasma from the 
mice. (90) Additionally, immune cells in the mice were not investigated, but future work 
could determine if the mice exhibit immune cell activation or senescence as observed in 
patients.  Finally, while aim 3 briefly quantified a plasma cholesterol and triglyceride 
levels, future work could expand this investigation of dyslipidemia to both the HIV Tg 
and AZT mice, to quantify HDL and LDL levels, and to increase the sample size.  All of 
this work will help to determine whether the mice exhibit systemic changes associated 
with HIV patients in addition to the vascular changes.     
 While the primary focus of this body of work was changes to the vasculature 
indicative of atherosclerosis, another interesting area of study would be related more to 
the cardiac function of CVD.  Specifically studies that assess ventricular size and ejection 
fraction may be useful to assess heart health and potential problems mediated by either 
the HIV proteins or antiretroviral drugs. Additional interesting work might include assess 
the hearts recovery capability to induced simulated heart attacks, which may provide 
insight into whether HIV patients are not only more prone to myocardial infarctions but 
also have a poorer prognosis following the event.    
 As previously addressed one limitation to this study is that the mice did not fully 
develop vascular disease, specifically atherosclerotic plaques, in the time course of the 




than a high fat diet which might more closely mimic diets of human patients that develop 
CVD.  Thus future studies using these same mouse models but administering a high fat 
diet to the mice might induce the formation of atherosclerotic plaques and allow the study 
of the full progression of the disease and the roles of HIV proteins and AZT.  Another 
option would be to conduct these tests in ApoE
-/-
 mice.  This knockout model is often 
used in atherosclerosis studies as the absence of the ApoE protein increases plasma 
cholesterol levels and leads to the development of fatty streaks and lesions.(182)  
Additional measurements that would be important to collect in these studies would be 
measurements of serum lipid levels including cholesterol and triglycerides. Dyslipidemia 
has been shown to occur in HIV patients and thus not only might these studies produce a 
more complete picture of plaque development but they may also provide insights into the 
roles that the viral proteins and drugs play in that syndrome.      
The models and tests performed in this study might also be applied to investigate 
other classes of the antiretroviral drugs.  This would be helpful in confirming and 
quantifying the suggestions in clinical literature that some classes of drugs have more 
deleterious effects on the vascular than others.  The implications of this work are that if it 
is known that certain drug classes (or drugs in particular) are more harmful than others in 
terms of cardiovascular health, treatment regimens can be optimized to try to balance 





APPENDIX A: CHAPTER 4 ADDITTIONAL PLOTS 
 
 
Figure A.1: HIV-1 protein expression increases arterial stiffness in carotids at a 
subphysiological stretch. Mechanical testing was used to investigate the biomechanics 
of carotid arteries. The results of the pressure-diameter mechanical tests at the 
subphysiological stretch of 1.4 show increased stiffness in the HIV Tg carotids in 
agreement with the results at physiological stretch in Figure 4.1. (* indicates p < 0.05, 





























Figure A.2: HIV-1 protein expression increases modulus (stiffness) in carotids at 
subphysiological and superphysiological stretches. Mechanical testing was used to 
investigate the biomechanics of carotid arteries. Peterson’s modulus, Ep, of the vessels 
was used to normalize for differences in vessel geometry The results at both 
subphysiological (λ=1.4) and superphysiological  (λ=1.9) stretches show increased 
moduli in the HIV Tg carotids in agreement with the results at physiological stretch in 













































































Figure A.3: HIV-1 protein expression increases modulus (stiffness) in aortas at 
subphysiological and superphysiological stretches. Mechanical testing was used to 
investigate the biomechanics of aortas arteries. Peterson’s modulus, Ep, of the vessels was 
used to normalize for differences in vessel geometry The results at both subphysiological 
(λ=1.4) and superphysiological  (λ=1.9) stretches show increased moduli in the HIV Tg 
aortas in agreement with the results at physiological stretch in Figure 4.1. (* indicates p < 












































































Figure A.4: Axial behavior at physiologically relevant load is not different between 
carotids from HIV Tg and wildtype mice.  Mechanical testing was also used to 
investigate the axial biomechanics of carotid arteries. Panel A shows the axial loads 
during pressure-diameter tests and the only differences are observed at subphysiological 
stretches.  Panel B is the results of the force-length tests with the only difference occur 

























































Figure A.4: Aortas from mice HIV Tg mice have increased cathepsin S and K and 
decreased cathepsin V activity. Cathepsin activity in the arterial wall was determined 
using zymography and densitometry to quantify the changes.  The results of the 
densitometry found increases in cathepsin S and K activity in the HIV Tg aortas, but a 
decrease in cathepsin V. These results were similar to those of the carotids in figure 4.7. 
(* indicates p < 0.05 N=5 (N=3 for cathepsin S and L) and data is mean +/- SEM) (Note: 



































APPENDIX B: CHAPTER 5 ADDITTIONAL PLOTS 
 
 
Figure B.1: AZT treatment increases arterial stiffness in aortas at a 
subphysiological stretch. Mechanical testing was used to investigate the biomechanics 
of aortas. The results of the pressure-diameter mechanical tests at the subphysiological 
stretch of 1.4 show increased stiffness in the AZT treated aortas in agreement with the 




Figure B.2: AZT treatment increases arterial stiffness in aortas at a 
subphysiological stretch. Mechanical testing was used to investigate the biomechanics 
of aortas and Peterson’s Modulus, a measure of arterial stiffness, was calculated from the 
pressure-diameter data.  At subphysiological stretch of 1.4, the aortas in the AZT treated 
mice showed increased stiffness in agreement with the results at physiological stretch in 
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